id	sid	tid	token	lemma	pos
ajst-21781	1	1	academic	academic	ADJ
ajst-21781	1	2	journal	journal	NOUN
ajst-21781	1	3	of	of	ADP
ajst-21781	1	4	science	science	NOUN
ajst-21781	1	5	and	and	CCONJ
ajst-21781	1	6	technology	technology	NOUN
ajst-21781	1	7	issn	issn	NOUN
ajst-21781	1	8	:	:	PUNCT
ajst-21781	1	9	2771	2771	NUM
ajst-21781	1	10	-	-	SYM
ajst-21781	1	11	3032	3032	NUM
ajst-21781	1	12	|	|	NOUN
ajst-21781	1	13	vol	vol	NOUN
ajst-21781	1	14	.	.	PROPN
ajst-21781	2	1	11	11	NUM
ajst-21781	2	2	,	,	PUNCT
ajst-21781	2	3	no	no	INTJ
ajst-21781	2	4	.	.	NOUN
ajst-21781	2	5	1	1	NUM
ajst-21781	2	6	,	,	PUNCT
ajst-21781	2	7	2024	2024	NUM
ajst-21781	2	8	166	166	NUM
ajst-21781	2	9	advances	advance	NOUN
ajst-21781	2	10	in	in	ADP
ajst-21781	2	11	the	the	DET
ajst-21781	2	12	study	study	NOUN
ajst-21781	2	13	of	of	ADP
ajst-21781	2	14	pde4	pde4	NOUN
ajst-21781	2	15	inhibitors	inhibitor	NOUN
ajst-21781	2	16	in	in	ADP
ajst-21781	2	17	dermatological	dermatological	ADJ
ajst-21781	2	18	disorders	disorder	NOUN
ajst-21781	2	19	wei	wei	PROPN
ajst-21781	2	20	jiang	jiang	PROPN
ajst-21781	2	21	1	1	NUM
ajst-21781	2	22	,	,	PUNCT
ajst-21781	2	23	*	*	PUNCT
ajst-21781	2	24	,	,	PUNCT
ajst-21781	2	25	xueyong	xueyong	PROPN
ajst-21781	2	26	wang1	wang1	PROPN
ajst-21781	2	27	,	,	PUNCT
ajst-21781	2	28	shan	shan	ADJ
ajst-21781	2	29	li1	li1	PROPN
ajst-21781	2	30	,	,	PUNCT
ajst-21781	2	31	nan	nan	PROPN
ajst-21781	2	32	li1	li1	PROPN
ajst-21781	2	33	,	,	PUNCT
ajst-21781	2	34	zhongwei	zhongwei	NOUN
ajst-21781	2	35	li1	li1	PROPN
ajst-21781	2	36	,	,	PUNCT
ajst-21781	2	37	zhiguo	zhiguo	PROPN
ajst-21781	2	38	xu1	xu1	PROPN
ajst-21781	2	39	1	1	NUM
ajst-21781	2	40	the	the	DET
ajst-21781	2	41	78th	78th	ADJ
ajst-21781	2	42	group	group	NOUN
ajst-21781	2	43	army	army	NOUN
ajst-21781	2	44	hospital	hospital	NOUN
ajst-21781	2	45	of	of	ADP
ajst-21781	2	46	chinese	chinese	ADJ
ajst-21781	2	47	pla	pla	PROPN
ajst-21781	2	48	,	,	PUNCT
ajst-21781	2	49	mudanjiang	mudanjiang	PROPN
ajst-21781	2	50	,	,	PUNCT
ajst-21781	2	51	china	china	PROPN
ajst-21781	2	52	*	*	PUNCT
ajst-21781	2	53	corresponding	correspond	VERB
ajst-21781	2	54	author	author	NOUN
ajst-21781	2	55	:	:	PUNCT
ajst-21781	2	56	wei	wei	PROPN
ajst-21781	2	57	jiang	jiang	PROPN
ajst-21781	2	58	abstract	abstract	PROPN
ajst-21781	2	59	:	:	PUNCT
ajst-21781	2	60	since	since	SCONJ
ajst-21781	2	61	the	the	DET
ajst-21781	2	62	1980s	1980s	NUM
ajst-21781	2	63	,	,	PUNCT
ajst-21781	2	64	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	2	65	4	4	NUM
ajst-21781	2	66	(	(	PUNCT
ajst-21781	2	67	pde-4	pde-4	NOUN
ajst-21781	2	68	)	)	PUNCT
ajst-21781	2	69	has	have	AUX
ajst-21781	2	70	been	be	AUX
ajst-21781	2	71	one	one	NUM
ajst-21781	2	72	of	of	ADP
ajst-21781	2	73	the	the	DET
ajst-21781	2	74	most	most	ADV
ajst-21781	2	75	prominent	prominent	ADJ
ajst-21781	2	76	targets	target	NOUN
ajst-21781	2	77	for	for	ADP
ajst-21781	2	78	the	the	DET
ajst-21781	2	79	treatment	treatment	NOUN
ajst-21781	2	80	of	of	ADP
ajst-21781	2	81	inflammatory	inflammatory	ADJ
ajst-21781	2	82	diseases	disease	NOUN
ajst-21781	2	83	.	.	PUNCT
ajst-21781	3	1	more	more	ADV
ajst-21781	3	2	recently	recently	ADV
ajst-21781	3	3	,	,	PUNCT
ajst-21781	3	4	a	a	DET
ajst-21781	3	5	number	number	NOUN
ajst-21781	3	6	of	of	ADP
ajst-21781	3	7	synthetic	synthetic	ADJ
ajst-21781	3	8	ligands	ligand	NOUN
ajst-21781	3	9	targeting	target	VERB
ajst-21781	3	10	pde-4	pde-4	NOUN
ajst-21781	3	11	have	have	AUX
ajst-21781	3	12	received	receive	VERB
ajst-21781	3	13	more	more	ADJ
ajst-21781	3	14	attention	attention	NOUN
ajst-21781	3	15	in	in	ADP
ajst-21781	3	16	the	the	DET
ajst-21781	3	17	academic	academic	ADJ
ajst-21781	3	18	and	and	CCONJ
ajst-21781	3	19	pharmaceutical	pharmaceutical	NOUN
ajst-21781	3	20	communities	community	NOUN
ajst-21781	3	21	and	and	CCONJ
ajst-21781	3	22	are	be	AUX
ajst-21781	3	23	expected	expect	VERB
ajst-21781	3	24	to	to	PART
ajst-21781	3	25	have	have	VERB
ajst-21781	3	26	applications	application	NOUN
ajst-21781	3	27	in	in	ADP
ajst-21781	3	28	these	these	DET
ajst-21781	3	29	diseases	disease	NOUN
ajst-21781	3	30	.	.	PUNCT
ajst-21781	4	1	due	due	ADP
ajst-21781	4	2	to	to	ADP
ajst-21781	4	3	various	various	ADJ
ajst-21781	4	4	potential	potential	ADJ
ajst-21781	4	5	side	side	NOUN
ajst-21781	4	6	effects	effect	NOUN
ajst-21781	4	7	of	of	ADP
ajst-21781	4	8	pde-4	pde-4	DET
ajst-21781	4	9	inhibitors	inhibitor	NOUN
ajst-21781	4	10	,	,	PUNCT
ajst-21781	4	11	there	there	PRON
ajst-21781	4	12	are	be	VERB
ajst-21781	4	13	several	several	ADJ
ajst-21781	4	14	obstacles	obstacle	NOUN
ajst-21781	4	15	to	to	ADP
ajst-21781	4	16	the	the	DET
ajst-21781	4	17	clinical	clinical	ADJ
ajst-21781	4	18	translation	translation	NOUN
ajst-21781	4	19	of	of	ADP
ajst-21781	4	20	specific	specific	ADJ
ajst-21781	4	21	pde-4	pde-4	NOUN
ajst-21781	4	22	inhibitors	inhibitor	NOUN
ajst-21781	4	23	from	from	ADP
ajst-21781	4	24	the	the	DET
ajst-21781	4	25	preclinical	preclinical	NOUN
ajst-21781	4	26	to	to	ADP
ajst-21781	4	27	the	the	DET
ajst-21781	4	28	clinical	clinical	ADJ
ajst-21781	4	29	phase	phase	NOUN
ajst-21781	4	30	.	.	PUNCT
ajst-21781	5	1	therefore	therefore	ADV
ajst-21781	5	2	,	,	PUNCT
ajst-21781	5	3	similar	similar	ADJ
ajst-21781	5	4	to	to	ADP
ajst-21781	5	5	roflumilast	roflumilast	NOUN
ajst-21781	5	6	in	in	ADP
ajst-21781	5	7	chronic	chronic	ADJ
ajst-21781	5	8	obstructive	obstructive	ADJ
ajst-21781	5	9	pulmonary	pulmonary	ADJ
ajst-21781	5	10	disease	disease	NOUN
ajst-21781	5	11	,	,	PUNCT
ajst-21781	5	12	many	many	ADJ
ajst-21781	5	13	pde-4	pde-4	NOUN
ajst-21781	5	14	inhibitors	inhibitor	NOUN
ajst-21781	5	15	can	can	AUX
ajst-21781	5	16	take	take	VERB
ajst-21781	5	17	up	up	ADV
ajst-21781	5	18	to	to	PART
ajst-21781	5	19	30	30	NUM
ajst-21781	5	20	years	year	NOUN
ajst-21781	5	21	or	or	CCONJ
ajst-21781	5	22	even	even	ADV
ajst-21781	5	23	longer	long	ADV
ajst-21781	5	24	from	from	ADP
ajst-21781	5	25	development	development	NOUN
ajst-21781	5	26	to	to	ADP
ajst-21781	5	27	clinical	clinical	ADJ
ajst-21781	5	28	application	application	NOUN
ajst-21781	5	29	.	.	PUNCT
ajst-21781	6	1	this	this	DET
ajst-21781	6	2	article	article	NOUN
ajst-21781	6	3	is	be	AUX
ajst-21781	6	4	a	a	DET
ajst-21781	6	5	review	review	NOUN
ajst-21781	6	6	of	of	ADP
ajst-21781	6	7	the	the	DET
ajst-21781	6	8	development	development	NOUN
ajst-21781	6	9	of	of	ADP
ajst-21781	6	10	pde-4	pde-4	NOUN
ajst-21781	6	11	inhibitors	inhibitor	NOUN
ajst-21781	6	12	,	,	PUNCT
ajst-21781	6	13	such	such	ADJ
ajst-21781	6	14	as	as	ADP
ajst-21781	6	15	crisaborole	crisaborole	NOUN
ajst-21781	6	16	and	and	CCONJ
ajst-21781	6	17	apremilast	apremilast	VERB
ajst-21781	6	18	,	,	PUNCT
ajst-21781	6	19	for	for	ADP
ajst-21781	6	20	use	use	NOUN
ajst-21781	6	21	in	in	ADP
ajst-21781	6	22	skin	skin	NOUN
ajst-21781	6	23	disorders	disorder	NOUN
ajst-21781	6	24	.	.	PUNCT
ajst-21781	7	1	keywords	keyword	NOUN
ajst-21781	7	2	:	:	PUNCT
ajst-21781	7	3	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	7	4	4	4	NUM
ajst-21781	7	5	inhibitor	inhibitor	NOUN
ajst-21781	7	6	;	;	PUNCT
ajst-21781	7	7	dermatological	dermatological	ADJ
ajst-21781	7	8	disorders	disorder	NOUN
ajst-21781	7	9	;	;	PUNCT
ajst-21781	7	10	camp	camp	NOUN
ajst-21781	7	11	-	-	PUNCT
ajst-21781	7	12	pka	pka	PROPN
ajst-21781	7	13	signaling	signal	VERB
ajst-21781	7	14	pathway	pathway	NOUN
ajst-21781	7	15	;	;	PUNCT
ajst-21781	7	16	apremilast	apremilast	ADJ
ajst-21781	7	17	;	;	PUNCT
ajst-21781	7	18	crisaborole	crisaborole	ADJ
ajst-21781	7	19	.	.	PUNCT
ajst-21781	8	1	1	1	X
ajst-21781	8	2	.	.	X
ajst-21781	8	3	introduction	introduction	NOUN
ajst-21781	8	4	the	the	DET
ajst-21781	8	5	discovery	discovery	NOUN
ajst-21781	8	6	of	of	ADP
ajst-21781	8	7	pdes	pde	NOUN
ajst-21781	8	8	by	by	ADP
ajst-21781	8	9	sutherland	sutherland	NOUN
ajst-21781	8	10	and	and	CCONJ
ajst-21781	8	11	rall	rall	PROPN
ajst-21781	8	12	in	in	ADP
ajst-21781	8	13	1958	1958	NUM
ajst-21781	8	14	has	have	AUX
ajst-21781	8	15	led	lead	VERB
ajst-21781	8	16	to	to	ADP
ajst-21781	8	17	extensive	extensive	ADJ
ajst-21781	8	18	research	research	NOUN
ajst-21781	8	19	into	into	ADP
ajst-21781	8	20	their	their	PRON
ajst-21781	8	21	active	active	ADJ
ajst-21781	8	22	modifications	modification	NOUN
ajst-21781	8	23	in	in	ADP
ajst-21781	8	24	the	the	DET
ajst-21781	8	25	medicinal	medicinal	ADJ
ajst-21781	8	26	chemistry	chemistry	NOUN
ajst-21781	8	27	community[1	community[1	NOUN
ajst-21781	8	28	]	]	PUNCT
ajst-21781	8	29	.	.	PUNCT
ajst-21781	9	1	pdes	pde	NOUN
ajst-21781	9	2	hydrolyse	hydrolyse	VERB
ajst-21781	9	3	the	the	DET
ajst-21781	9	4	phosphodiester	phosphodiester	ADJ
ajst-21781	9	5	bond	bond	NOUN
ajst-21781	9	6	of	of	ADP
ajst-21781	9	7	c	c	NOUN
ajst-21781	9	8	-	-	PUNCT
ajst-21781	9	9	amp	amp	NOUN
ajst-21781	9	10	and	and	CCONJ
ajst-21781	9	11	c	c	NOUN
ajst-21781	9	12	-	-	PUNCT
ajst-21781	9	13	gmp	gmp	PROPN
ajst-21781	9	14	to	to	PART
ajst-21781	9	15	form	form	VERB
ajst-21781	9	16	two	two	NUM
ajst-21781	9	17	biologically	biologically	ADV
ajst-21781	9	18	inactive	inactive	ADJ
ajst-21781	9	19	substances	substance	NOUN
ajst-21781	9	20	,	,	PUNCT
ajst-21781	9	21	amp	amp	NOUN
ajst-21781	9	22	and	and	CCONJ
ajst-21781	9	23	gmp[2	gmp[2	NUM
ajst-21781	9	24	-	-	SYM
ajst-21781	9	25	4	4	NUM
ajst-21781	9	26	]	]	PUNCT
ajst-21781	9	27	.	.	PUNCT
ajst-21781	10	1	in	in	ADP
ajst-21781	10	2	fact	fact	NOUN
ajst-21781	10	3	,	,	PUNCT
ajst-21781	10	4	inhibition	inhibition	NOUN
ajst-21781	10	5	of	of	ADP
ajst-21781	10	6	pdes	pde	NOUN
ajst-21781	10	7	can	can	AUX
ajst-21781	10	8	elevate	elevate	VERB
ajst-21781	10	9	cyclic	cyclic	ADJ
ajst-21781	10	10	nucleotide	nucleotide	NOUN
ajst-21781	10	11	levels	level	NOUN
ajst-21781	10	12	and	and	CCONJ
ajst-21781	10	13	thus	thus	ADV
ajst-21781	10	14	act	act	VERB
ajst-21781	10	15	as	as	ADP
ajst-21781	10	16	a	a	DET
ajst-21781	10	17	second	second	ADJ
ajst-21781	10	18	messenger	messenger	NOUN
ajst-21781	10	19	,	,	PUNCT
ajst-21781	10	20	exerting	exert	VERB
ajst-21781	10	21	physiopathological	physiopathological	ADJ
ajst-21781	10	22	regulation	regulation	NOUN
ajst-21781	10	23	in	in	ADP
ajst-21781	10	24	secretion	secretion	NOUN
ajst-21781	10	25	,	,	PUNCT
ajst-21781	10	26	contraction	contraction	NOUN
ajst-21781	10	27	,	,	PUNCT
ajst-21781	10	28	metabolism	metabolism	NOUN
ajst-21781	10	29	and	and	CCONJ
ajst-21781	10	30	proliferation[5	proliferation[5	NOUN
ajst-21781	10	31	]	]	PUNCT
ajst-21781	10	32	.	.	PUNCT
ajst-21781	11	1	the	the	DET
ajst-21781	11	2	pdes	pde	NOUN
ajst-21781	11	3	superfamily	superfamily	ADV
ajst-21781	11	4	is	be	AUX
ajst-21781	11	5	divided	divide	VERB
ajst-21781	11	6	into	into	ADP
ajst-21781	11	7	11	11	NUM
ajst-21781	11	8	species	specie	NOUN
ajst-21781	11	9	,	,	PUNCT
ajst-21781	11	10	ranging	range	VERB
ajst-21781	11	11	from	from	ADP
ajst-21781	11	12	pde1	pde1	ADJ
ajst-21781	11	13	-	-	PUNCT
ajst-21781	11	14	pde11[6	pde11[6	NOUN
ajst-21781	11	15	]	]	X
ajst-21781	11	16	.	.	PUNCT
ajst-21781	12	1	pde-4	pde-4	PUNCT
ajst-21781	12	2	is	be	AUX
ajst-21781	12	3	currently	currently	ADV
ajst-21781	12	4	the	the	DET
ajst-21781	12	5	most	most	ADV
ajst-21781	12	6	diverse	diverse	ADJ
ajst-21781	12	7	subfamily	subfamily	ADV
ajst-21781	12	8	of	of	ADP
ajst-21781	12	9	pdes	pde	NOUN
ajst-21781	12	10	and	and	CCONJ
ajst-21781	12	11	is	be	AUX
ajst-21781	12	12	widely	widely	ADV
ajst-21781	12	13	expressed	express	VERB
ajst-21781	12	14	in	in	ADP
ajst-21781	12	15	a	a	DET
ajst-21781	12	16	variety	variety	NOUN
ajst-21781	12	17	of	of	ADP
ajst-21781	12	18	cell	cell	NOUN
ajst-21781	12	19	types[6,7	types[6,7	PROPN
ajst-21781	12	20	]	]	PUNCT
ajst-21781	12	21	.	.	PUNCT
ajst-21781	13	1	these	these	DET
ajst-21781	13	2	enzymes	enzyme	NOUN
ajst-21781	13	3	are	be	AUX
ajst-21781	13	4	intimately	intimately	ADV
ajst-21781	13	5	involved	involve	VERB
ajst-21781	13	6	in	in	ADP
ajst-21781	13	7	a	a	DET
ajst-21781	13	8	variety	variety	NOUN
ajst-21781	13	9	of	of	ADP
ajst-21781	13	10	physiological	physiological	ADJ
ajst-21781	13	11	activities	activity	NOUN
ajst-21781	13	12	such	such	ADJ
ajst-21781	13	13	as	as	ADP
ajst-21781	13	14	brain	brain	NOUN
ajst-21781	13	15	function	function	NOUN
ajst-21781	13	16	,	,	PUNCT
ajst-21781	13	17	phagocyte	phagocyte	NOUN
ajst-21781	13	18	/	/	SYM
ajst-21781	13	19	monocyte	monocyte	NOUN
ajst-21781	13	20	activation	activation	NOUN
ajst-21781	13	21	,	,	PUNCT
ajst-21781	13	22	cardiomyocyte	cardiomyocyte	NOUN
ajst-21781	13	23	contraction	contraction	NOUN
ajst-21781	13	24	,	,	PUNCT
ajst-21781	13	25	vascular	vascular	ADJ
ajst-21781	13	26	smooth	smooth	ADJ
ajst-21781	13	27	muscle	muscle	NOUN
ajst-21781	13	28	proliferation	proliferation	NOUN
ajst-21781	13	29	and	and	CCONJ
ajst-21781	13	30	neutrophil	neutrophil	ADJ
ajst-21781	13	31	infiltration	infiltration	NOUN
ajst-21781	13	32	,	,	PUNCT
ajst-21781	13	33	to	to	PART
ajst-21781	13	34	name	name	VERB
ajst-21781	13	35	a	a	DET
ajst-21781	13	36	few	few	ADJ
ajst-21781	13	37	.	.	PUNCT
ajst-21781	14	1	in	in	ADP
ajst-21781	14	2	addition	addition	NOUN
ajst-21781	14	3	,	,	PUNCT
ajst-21781	14	4	pde-4	pde-4	PUNCT
ajst-21781	14	5	may	may	AUX
ajst-21781	14	6	be	be	AUX
ajst-21781	14	7	closely	closely	ADV
ajst-21781	14	8	involved	involve	VERB
ajst-21781	14	9	in	in	ADP
ajst-21781	14	10	the	the	DET
ajst-21781	14	11	development	development	NOUN
ajst-21781	14	12	of	of	ADP
ajst-21781	14	13	autoimmune	autoimmune	ADJ
ajst-21781	14	14	diseases	disease	NOUN
ajst-21781	14	15	,	,	PUNCT
ajst-21781	14	16	tumours	tumour	NOUN
ajst-21781	14	17	and	and	CCONJ
ajst-21781	14	18	cardiovascular	cardiovascular	ADJ
ajst-21781	14	19	diseases[8	diseases[8	PROPN
ajst-21781	14	20	]	]	PUNCT
ajst-21781	14	21	.	.	PUNCT
ajst-21781	15	1	there	there	PRON
ajst-21781	15	2	are	be	VERB
ajst-21781	15	3	four	four	NUM
ajst-21781	15	4	isoforms	isoform	NOUN
ajst-21781	15	5	of	of	ADP
ajst-21781	15	6	pde-4	pde-4	NOUN
ajst-21781	15	7	,	,	PUNCT
ajst-21781	15	8	namely	namely	ADV
ajst-21781	15	9	pde-4a	pde-4a	ADJ
ajst-21781	15	10	,	,	PUNCT
ajst-21781	15	11	pde4b	pde4b	NOUN
ajst-21781	15	12	,	,	PUNCT
ajst-21781	15	13	pde-4c	pde-4c	NOUN
ajst-21781	15	14	and	and	CCONJ
ajst-21781	15	15	pde-4d[9	pde-4d[9	NOUN
ajst-21781	15	16	]	]	X
ajst-21781	15	17	.	.	PUNCT
ajst-21781	16	1	all	all	DET
ajst-21781	16	2	pde-4s	pde-4s	PROPN
ajst-21781	16	3	have	have	VERB
ajst-21781	16	4	ucr	ucr	PROPN
ajst-21781	16	5	conserved	conserve	VERB
ajst-21781	16	6	domains	domain	NOUN
ajst-21781	16	7	in	in	ADP
ajst-21781	16	8	the	the	DET
ajst-21781	16	9	n	n	CCONJ
ajst-21781	16	10	-	-	PUNCT
ajst-21781	16	11	terminal	terminal	ADJ
ajst-21781	16	12	region	region	NOUN
ajst-21781	16	13	that	that	PRON
ajst-21781	16	14	are	be	AUX
ajst-21781	16	15	intimately	intimately	ADV
ajst-21781	16	16	involved	involve	VERB
ajst-21781	16	17	in	in	ADP
ajst-21781	16	18	the	the	DET
ajst-21781	16	19	transcriptional	transcriptional	ADJ
ajst-21781	16	20	and	and	CCONJ
ajst-21781	16	21	translational	translational	ADJ
ajst-21781	16	22	regulation	regulation	NOUN
ajst-21781	16	23	of	of	ADP
ajst-21781	16	24	pde-4	pde-4	NOUN
ajst-21781	16	25	.	.	PUNCT
ajst-21781	16	26	pde-4	pde-4	NOUN
ajst-21781	16	27	has	have	VERB
ajst-21781	16	28	a	a	DET
ajst-21781	16	29	catalytic	catalytic	ADJ
ajst-21781	16	30	domain	domain	NOUN
ajst-21781	16	31	in	in	ADP
ajst-21781	16	32	the	the	DET
ajst-21781	16	33	cterminus	cterminus	NOUN
ajst-21781	16	34	,	,	PUNCT
ajst-21781	16	35	which	which	PRON
ajst-21781	16	36	usually	usually	ADV
ajst-21781	16	37	consists	consist	VERB
ajst-21781	16	38	of	of	ADP
ajst-21781	16	39	300	300	NUM
ajst-21781	16	40	-	-	SYM
ajst-21781	16	41	350	350	NUM
ajst-21781	16	42	amino	amino	NOUN
ajst-21781	16	43	acids[6	acids[6	ADP
ajst-21781	16	44	]	]	PUNCT
ajst-21781	16	45	.	.	PUNCT
ajst-21781	17	1	2	2	X
ajst-21781	17	2	.	.	X
ajst-21781	17	3	inflammation	inflammation	NOUN
ajst-21781	17	4	and	and	CCONJ
ajst-21781	17	5	pde-4	pde-4	PUNCT
ajst-21781	17	6	nuclear	nuclear	ADJ
ajst-21781	17	7	factor	factor	NOUN
ajst-21781	17	8	κ	κ	NOUN
ajst-21781	17	9	-	-	PUNCT
ajst-21781	17	10	light	light	ADJ
ajst-21781	17	11	-	-	PUNCT
ajst-21781	17	12	chain	chain	NOUN
ajst-21781	17	13	-	-	PUNCT
ajst-21781	17	14	enhancer	enhancer	NOUN
ajst-21781	17	15	of	of	ADP
ajst-21781	17	16	activated	activate	VERB
ajst-21781	17	17	b	b	PROPN
ajst-21781	17	18	cells	cell	NOUN
ajst-21781	17	19	(	(	PUNCT
ajst-21781	17	20	nf	nf	NOUN
ajst-21781	17	21	-	-	PUNCT
ajst-21781	17	22	κb	κb	NOUN
ajst-21781	17	23	)	)	PUNCT
ajst-21781	17	24	is	be	AUX
ajst-21781	17	25	known	know	VERB
ajst-21781	17	26	to	to	PART
ajst-21781	17	27	mediate	mediate	VERB
ajst-21781	17	28	specific	specific	ADJ
ajst-21781	17	29	responses	response	NOUN
ajst-21781	17	30	,	,	PUNCT
ajst-21781	17	31	and	and	CCONJ
ajst-21781	17	32	pharmacological	pharmacological	ADJ
ajst-21781	17	33	blockade	blockade	NOUN
ajst-21781	17	34	of	of	ADP
ajst-21781	17	35	nf	nf	ADJ
ajst-21781	17	36	-	-	PUNCT
ajst-21781	17	37	κb	κb	NOUN
ajst-21781	17	38	activity	activity	NOUN
ajst-21781	17	39	can	can	AUX
ajst-21781	17	40	be	be	AUX
ajst-21781	17	41	used	use	VERB
ajst-21781	17	42	to	to	PART
ajst-21781	17	43	therapeutically	therapeutically	ADV
ajst-21781	17	44	control	control	VERB
ajst-21781	17	45	inflammatory	inflammatory	ADJ
ajst-21781	17	46	diseases[6	diseases[6	PROPN
ajst-21781	17	47	]	]	PUNCT
ajst-21781	17	48	.	.	PUNCT
ajst-21781	18	1	c	c	X
ajst-21781	18	2	-	-	PUNCT
ajst-21781	18	3	amp	amp	NOUN
ajst-21781	18	4	can	can	AUX
ajst-21781	18	5	inhibit	inhibit	VERB
ajst-21781	18	6	signal	signal	VERB
ajst-21781	18	7	transduction	transduction	NOUN
ajst-21781	18	8	downstream	downstream	NOUN
ajst-21781	18	9	of	of	ADP
ajst-21781	18	10	the	the	DET
ajst-21781	18	11	nf	nf	ADJ
ajst-21781	18	12	-	-	PUNCT
ajst-21781	18	13	κb	κb	NOUN
ajst-21781	18	14	pathway	pathway	NOUN
ajst-21781	18	15	,	,	PUNCT
ajst-21781	18	16	and	and	CCONJ
ajst-21781	18	17	c	c	X
ajst-21781	18	18	-	-	PUNCT
ajst-21781	18	19	amp	amp	NOUN
ajst-21781	18	20	levels	level	NOUN
ajst-21781	18	21	are	be	AUX
ajst-21781	18	22	positively	positively	ADV
ajst-21781	18	23	correlated	correlate	VERB
ajst-21781	18	24	with	with	ADP
ajst-21781	18	25	immunosuppressive	immunosuppressive	ADJ
ajst-21781	18	26	and	and	CCONJ
ajst-21781	18	27	anti	anti	ADJ
ajst-21781	18	28	-	-	ADJ
ajst-21781	18	29	inflammatory	inflammatory	ADJ
ajst-21781	18	30	effects[6,10,11	effects[6,10,11	NOUN
ajst-21781	18	31	]	]	PUNCT
ajst-21781	18	32	.	.	PUNCT
ajst-21781	19	1	since	since	SCONJ
ajst-21781	19	2	pde-4	pde-4	NOUN
ajst-21781	19	3	can	can	AUX
ajst-21781	19	4	hydrolyse	hydrolyse	VERB
ajst-21781	19	5	c	c	NOUN
ajst-21781	19	6	-	-	PUNCT
ajst-21781	19	7	amp	amp	NOUN
ajst-21781	19	8	,	,	PUNCT
ajst-21781	19	9	it	it	PRON
ajst-21781	19	10	could	could	AUX
ajst-21781	19	11	be	be	AUX
ajst-21781	19	12	a	a	DET
ajst-21781	19	13	key	key	ADJ
ajst-21781	19	14	target	target	NOUN
ajst-21781	19	15	in	in	ADP
ajst-21781	19	16	the	the	DET
ajst-21781	19	17	treatment	treatment	NOUN
ajst-21781	19	18	of	of	ADP
ajst-21781	19	19	inflammatory	inflammatory	ADJ
ajst-21781	19	20	diseases	disease	NOUN
ajst-21781	19	21	by	by	ADP
ajst-21781	19	22	modulating	modulate	VERB
ajst-21781	19	23	the	the	DET
ajst-21781	19	24	nfκb	nfκb	NOUN
ajst-21781	19	25	pathway[9	pathway[9	PROPN
ajst-21781	19	26	]	]	PUNCT
ajst-21781	19	27	.	.	PUNCT
ajst-21781	20	1	macrophages	macrophage	NOUN
ajst-21781	20	2	exposed	expose	VERB
ajst-21781	20	3	to	to	ADP
ajst-21781	20	4	ethanol	ethanol	NOUN
ajst-21781	20	5	for	for	ADP
ajst-21781	20	6	a	a	DET
ajst-21781	20	7	long	long	ADJ
ajst-21781	20	8	time	time	NOUN
ajst-21781	20	9	can	can	AUX
ajst-21781	20	10	inhibit	inhibit	VERB
ajst-21781	20	11	tnf	tnf	PROPN
ajst-21781	20	12	-	-	PUNCT
ajst-21781	20	13	α	α	PROPN
ajst-21781	20	14	mrna	mrna	NOUN
ajst-21781	20	15	expression	expression	NOUN
ajst-21781	20	16	by	by	ADP
ajst-21781	20	17	inhibiting	inhibit	VERB
ajst-21781	20	18	pde4	pde4	NOUN
ajst-21781	20	19	,	,	PUNCT
ajst-21781	20	20	and	and	CCONJ
ajst-21781	20	21	inhibition	inhibition	NOUN
ajst-21781	20	22	of	of	ADP
ajst-21781	20	23	pde-4	pde-4	PRON
ajst-21781	20	24	not	not	PART
ajst-21781	20	25	only	only	ADV
ajst-21781	20	26	inhibits	inhibit	VERB
ajst-21781	20	27	the	the	DET
ajst-21781	20	28	nf	nf	ADJ
ajst-21781	20	29	-	-	PUNCT
ajst-21781	20	30	κb	κb	NOUN
ajst-21781	20	31	-	-	PUNCT
ajst-21781	20	32	tnfα	tnfα	NOUN
ajst-21781	20	33	pathway	pathway	NOUN
ajst-21781	20	34	,	,	PUNCT
ajst-21781	20	35	but	but	CCONJ
ajst-21781	20	36	also	also	ADV
ajst-21781	20	37	activates	activate	VERB
ajst-21781	20	38	pka	pka	PROPN
ajst-21781	20	39	and	and	CCONJ
ajst-21781	20	40	induces	induce	VERB
ajst-21781	20	41	the	the	DET
ajst-21781	20	42	expression	expression	NOUN
ajst-21781	20	43	of	of	ADP
ajst-21781	20	44	il-10[8	il-10[8	NOUN
ajst-21781	20	45	]	]	PUNCT
ajst-21781	20	46	.	.	PUNCT
ajst-21781	21	1	thus	thus	ADV
ajst-21781	21	2	,	,	PUNCT
ajst-21781	21	3	pde-4	pde-4	DET
ajst-21781	21	4	inhibitors	inhibitor	NOUN
ajst-21781	21	5	may	may	AUX
ajst-21781	21	6	play	play	VERB
ajst-21781	21	7	an	an	DET
ajst-21781	21	8	important	important	ADJ
ajst-21781	21	9	role	role	NOUN
ajst-21781	21	10	in	in	ADP
ajst-21781	21	11	the	the	DET
ajst-21781	21	12	negative	negative	ADJ
ajst-21781	21	13	and	and	CCONJ
ajst-21781	21	14	positive	positive	ADJ
ajst-21781	21	15	regulation	regulation	NOUN
ajst-21781	21	16	of	of	ADP
ajst-21781	21	17	gene	gene	NOUN
ajst-21781	21	18	expression[8	expression[8	PROPN
ajst-21781	21	19	]	]	PUNCT
ajst-21781	21	20	.	.	PUNCT
ajst-21781	22	1	in	in	ADP
ajst-21781	22	2	t	t	PROPN
ajst-21781	22	3	lymphocytes	lymphocyte	NOUN
ajst-21781	22	4	,	,	PUNCT
ajst-21781	22	5	both	both	PRON
ajst-21781	22	6	pde-4	pde-4	ADJ
ajst-21781	22	7	and	and	CCONJ
ajst-21781	22	8	c	c	X
ajst-21781	22	9	-	-	PUNCT
ajst-21781	22	10	amp	amp	NOUN
ajst-21781	22	11	have	have	AUX
ajst-21781	22	12	been	be	AUX
ajst-21781	22	13	reported	report	VERB
ajst-21781	22	14	to	to	PART
ajst-21781	22	15	be	be	AUX
ajst-21781	22	16	involved	involve	VERB
ajst-21781	22	17	in	in	ADP
ajst-21781	22	18	the	the	DET
ajst-21781	22	19	regulation	regulation	NOUN
ajst-21781	22	20	of	of	ADP
ajst-21781	22	21	their	their	PRON
ajst-21781	22	22	proliferation	proliferation	NOUN
ajst-21781	22	23	,	,	PUNCT
ajst-21781	22	24	expression	expression	NOUN
ajst-21781	22	25	of	of	ADP
ajst-21781	22	26	tnf	tnf	PROPN
ajst-21781	22	27	-	-	PUNCT
ajst-21781	22	28	α	α	PROPN
ajst-21781	22	29	and	and	CCONJ
ajst-21781	22	30	other	other	ADJ
ajst-21781	22	31	interleukins	interleukin	NOUN
ajst-21781	22	32	(	(	PUNCT
ajst-21781	22	33	il-2	il-2	NUM
ajst-21781	22	34	,	,	PUNCT
ajst-21781	22	35	il-4	il-4	NOUN
ajst-21781	22	36	and	and	CCONJ
ajst-21781	22	37	il-5)[12	il-5)[12	PROPN
ajst-21781	22	38	]	]	PUNCT
ajst-21781	22	39	.	.	PUNCT
ajst-21781	23	1	by	by	ADP
ajst-21781	23	2	cross	cros	VERB
ajst-21781	23	3	-	-	ADJ
ajst-21781	23	4	linking	link	VERB
ajst-21781	23	5	with	with	ADP
ajst-21781	23	6	t	t	NOUN
ajst-21781	23	7	cell	cell	NOUN
ajst-21781	23	8	membranes	membrane	NOUN
ajst-21781	23	9	(	(	PUNCT
ajst-21781	23	10	e.g.	e.g.	ADV
ajst-21781	23	11	cd4	cd4	ADJ
ajst-21781	23	12	-	-	ADJ
ajst-21781	23	13	positive	positive	ADJ
ajst-21781	23	14	and	and	CCONJ
ajst-21781	23	15	th2	th2	PROPN
ajst-21781	23	16	subsets	subset	NOUN
ajst-21781	23	17	)	)	PUNCT
ajst-21781	23	18	,	,	PUNCT
ajst-21781	23	19	c	c	X
ajst-21781	23	20	-	-	PUNCT
ajst-21781	23	21	amp	amp	NOUN
ajst-21781	23	22	can	can	AUX
ajst-21781	23	23	also	also	ADV
ajst-21781	23	24	inhibit	inhibit	VERB
ajst-21781	23	25	t	t	NOUN
ajst-21781	23	26	cell	cell	NOUN
ajst-21781	23	27	proliferation	proliferation	NOUN
ajst-21781	23	28	by	by	ADP
ajst-21781	23	29	acting	act	VERB
ajst-21781	23	30	as	as	ADP
ajst-21781	23	31	a	a	DET
ajst-21781	23	32	regulator	regulator	NOUN
ajst-21781	23	33	of	of	ADP
ajst-21781	23	34	t	t	PROPN
ajst-21781	23	35	cells[7	cells[7	PROPN
ajst-21781	23	36	]	]	PUNCT
ajst-21781	23	37	.	.	PUNCT
ajst-21781	24	1	in	in	ADP
ajst-21781	24	2	terms	term	NOUN
ajst-21781	24	3	of	of	ADP
ajst-21781	24	4	inflammatory	inflammatory	ADJ
ajst-21781	24	5	regulation	regulation	NOUN
ajst-21781	24	6	,	,	PUNCT
ajst-21781	24	7	pde-4	pde-4	PUNCT
ajst-21781	24	8	may	may	AUX
ajst-21781	24	9	be	be	AUX
ajst-21781	24	10	involved	involve	VERB
ajst-21781	24	11	in	in	ADP
ajst-21781	24	12	the	the	DET
ajst-21781	24	13	regulation	regulation	NOUN
ajst-21781	24	14	of	of	ADP
ajst-21781	24	15	eosinophil	eosinophil	ADJ
ajst-21781	24	16	and	and	CCONJ
ajst-21781	24	17	neutrophil	neutrophil	ADJ
ajst-21781	24	18	chemotaxis	chemotaxis	NOUN
ajst-21781	24	19	and	and	CCONJ
ajst-21781	24	20	degranulation[7,8	degranulation[7,8	NUM
ajst-21781	24	21	]	]	PUNCT
ajst-21781	24	22	.	.	PUNCT
ajst-21781	25	1	these	these	DET
ajst-21781	25	2	effects	effect	NOUN
ajst-21781	25	3	are	be	AUX
ajst-21781	25	4	mediated	mediate	VERB
ajst-21781	25	5	by	by	ADP
ajst-21781	25	6	pde-4	pde-4	NOUN
ajst-21781	25	7	-	-	PUNCT
ajst-21781	25	8	mediated	mediate	VERB
ajst-21781	25	9	increases	increase	NOUN
ajst-21781	25	10	in	in	ADP
ajst-21781	25	11	il-8	il-8	NOUN
ajst-21781	25	12	,	,	PUNCT
ajst-21781	25	13	leukotriene	leukotriene	NOUN
ajst-21781	25	14	b4	b4	NOUN
ajst-21781	25	15	and	and	CCONJ
ajst-21781	25	16	superoxide	superoxide	NOUN
ajst-21781	25	17	anion	anion	NOUN
ajst-21781	25	18	levels	level	NOUN
ajst-21781	25	19	in	in	ADP
ajst-21781	25	20	neutrophils	neutrophil	NOUN
ajst-21781	25	21	.	.	PUNCT
ajst-21781	26	1	in	in	ADP
ajst-21781	26	2	addition	addition	NOUN
ajst-21781	26	3	,	,	PUNCT
ajst-21781	26	4	pde-4	pde-4	PUNCT
ajst-21781	26	5	is	be	AUX
ajst-21781	26	6	involved	involve	VERB
ajst-21781	26	7	in	in	ADP
ajst-21781	26	8	the	the	DET
ajst-21781	26	9	regulation	regulation	NOUN
ajst-21781	26	10	of	of	ADP
ajst-21781	26	11	adhesion	adhesion	NOUN
ajst-21781	26	12	molecules	molecule	NOUN
ajst-21781	26	13	such	such	ADJ
ajst-21781	26	14	as	as	ADP
ajst-21781	26	15	the	the	DET
ajst-21781	26	16	β2	β2	PROPN
ajst-21781	26	17	integrin	integrin	NOUN
ajst-21781	26	18	mac-1	mac-1	VERB
ajst-21781	26	19	in	in	ADP
ajst-21781	26	20	neutrophils	neutrophil	NOUN
ajst-21781	26	21	,	,	PUNCT
ajst-21781	26	22	thereby	thereby	ADV
ajst-21781	26	23	enhancing	enhance	VERB
ajst-21781	26	24	their	their	PRON
ajst-21781	26	25	adhesion	adhesion	NOUN
ajst-21781	26	26	to	to	PART
ajst-21781	26	27	vascular	vascular	VERB
ajst-21781	26	28	endothelial	endothelial	ADJ
ajst-21781	26	29	cells[8,13	cells[8,13	NOUN
ajst-21781	26	30	]	]	PUNCT
ajst-21781	26	31	.	.	PUNCT
ajst-21781	27	1	3	3	X
ajst-21781	27	2	.	.	X
ajst-21781	27	3	pde-4	pde-4	NOUN
ajst-21781	27	4	inhibitors	inhibitor	NOUN
ajst-21781	27	5	and	and	CCONJ
ajst-21781	27	6	atopic	atopic	NOUN
ajst-21781	27	7	dermatitis	dermatitis	NOUN
ajst-21781	27	8	(	(	PUNCT
ajst-21781	27	9	ad	ad	NOUN
ajst-21781	27	10	)	)	PUNCT
ajst-21781	27	11	atopic	atopic	NOUN
ajst-21781	27	12	dermatitis	dermatitis	NOUN
ajst-21781	27	13	(	(	PUNCT
ajst-21781	27	14	ad	ad	NOUN
ajst-21781	27	15	)	)	PUNCT
ajst-21781	27	16	is	be	AUX
ajst-21781	27	17	a	a	DET
ajst-21781	27	18	chronic	chronic	ADJ
ajst-21781	27	19	inflammatory	inflammatory	ADJ
ajst-21781	27	20	skin	skin	NOUN
ajst-21781	27	21	disease	disease	NOUN
ajst-21781	27	22	with	with	ADP
ajst-21781	27	23	a	a	DET
ajst-21781	27	24	prevalence	prevalence	NOUN
ajst-21781	27	25	of	of	ADP
ajst-21781	27	26	approximately	approximately	ADV
ajst-21781	27	27	2	2	NUM
ajst-21781	27	28	-	-	SYM
ajst-21781	27	29	3	3	NUM
ajst-21781	27	30	%	%	NOUN
ajst-21781	27	31	and	and	CCONJ
ajst-21781	27	32	an	an	DET
ajst-21781	27	33	increasing	increase	VERB
ajst-21781	27	34	trend	trend	NOUN
ajst-21781	27	35	over	over	ADP
ajst-21781	27	36	the	the	DET
ajst-21781	27	37	years[6	years[6	PRON
ajst-21781	27	38	]	]	PUNCT
ajst-21781	27	39	.	.	PUNCT
ajst-21781	28	1	the	the	DET
ajst-21781	28	2	main	main	ADJ
ajst-21781	28	3	manifestations	manifestation	NOUN
ajst-21781	28	4	of	of	ADP
ajst-21781	28	5	ad	ad	NOUN
ajst-21781	28	6	are	be	AUX
ajst-21781	28	7	recurrent	recurrent	ADJ
ajst-21781	28	8	pruritus	pruritus	NOUN
ajst-21781	28	9	,	,	PUNCT
ajst-21781	28	10	skin	skin	NOUN
ajst-21781	28	11	hypersensitivity	hypersensitivity	NOUN
ajst-21781	28	12	and	and	CCONJ
ajst-21781	28	13	erythema	erythema	ADJ
ajst-21781	28	14	,	,	PUNCT
ajst-21781	28	15	and	and	CCONJ
ajst-21781	28	16	there	there	PRON
ajst-21781	28	17	is	be	VERB
ajst-21781	28	18	considerable	considerable	ADJ
ajst-21781	28	19	evidence	evidence	NOUN
ajst-21781	28	20	that	that	SCONJ
ajst-21781	28	21	immune	immune	ADJ
ajst-21781	28	22	and	and	CCONJ
ajst-21781	28	23	inflammatory	inflammatory	ADJ
ajst-21781	28	24	cells	cell	NOUN
ajst-21781	28	25	are	be	AUX
ajst-21781	28	26	closely	closely	ADV
ajst-21781	28	27	involved	involve	VERB
ajst-21781	28	28	in	in	ADP
ajst-21781	28	29	the	the	DET
ajst-21781	28	30	pathogenesis	pathogenesis	NOUN
ajst-21781	28	31	of	of	ADP
ajst-21781	28	32	ad[14	ad[14	PROPN
ajst-21781	28	33	]	]	X
ajst-21781	28	34	.	.	PUNCT
ajst-21781	29	1	current	current	ADJ
ajst-21781	29	2	treatment	treatment	NOUN
ajst-21781	29	3	for	for	ADP
ajst-21781	29	4	ad	ad	NOUN
ajst-21781	29	5	consists	consist	NOUN
ajst-21781	29	6	of	of	ADP
ajst-21781	29	7	moisturising	moisturise	VERB
ajst-21781	29	8	the	the	DET
ajst-21781	29	9	skin	skin	NOUN
ajst-21781	29	10	,	,	PUNCT
ajst-21781	29	11	topical	topical	ADJ
ajst-21781	29	12	steroids	steroid	NOUN
ajst-21781	29	13	(	(	PUNCT
ajst-21781	29	14	e.g.	e.g.	ADV
ajst-21781	29	15	hydrocortisone	hydrocortisone	PROPN
ajst-21781	29	16	,	,	PUNCT
ajst-21781	29	17	betamethasone	betamethasone	NOUN
ajst-21781	29	18	and	and	CCONJ
ajst-21781	29	19	clobetasol	clobetasol	NOUN
ajst-21781	29	20	)	)	PUNCT
ajst-21781	29	21	and	and	CCONJ
ajst-21781	29	22	topical	topical	ADJ
ajst-21781	29	23	calcineurin	calcineurin	NOUN
ajst-21781	29	24	inhibitors	inhibitor	NOUN
ajst-21781	29	25	(	(	PUNCT
ajst-21781	29	26	tacrolimus	tacrolimus	NOUN
ajst-21781	29	27	,	,	PUNCT
ajst-21781	29	28	pimecrolimus)[14	pimecrolimus)[14	PROPN
ajst-21781	29	29	]	]	PUNCT
ajst-21781	29	30	.	.	PUNCT
ajst-21781	30	1	in	in	ADP
ajst-21781	30	2	december	december	PROPN
ajst-21781	30	3	2016	2016	NUM
ajst-21781	30	4	,	,	PUNCT
ajst-21781	30	5	crisaborole	crisaborole	NOUN
ajst-21781	30	6	,	,	PUNCT
ajst-21781	30	7	manufactured	manufacture	VERB
ajst-21781	30	8	by	by	ADP
ajst-21781	30	9	pfizer	pfizer	NOUN
ajst-21781	30	10	,	,	PUNCT
ajst-21781	30	11	was	be	AUX
ajst-21781	30	12	approved	approve	VERB
ajst-21781	30	13	for	for	ADP
ajst-21781	30	14	topical	topical	ADJ
ajst-21781	30	15	use	use	NOUN
ajst-21781	30	16	in	in	ADP
ajst-21781	30	17	the	the	DET
ajst-21781	30	18	treatment	treatment	NOUN
ajst-21781	30	19	of	of	ADP
ajst-21781	30	20	ad[8,14,15	ad[8,14,15	NUM
ajst-21781	30	21	]	]	PUNCT
ajst-21781	30	22	.	.	PUNCT
ajst-21781	31	1	although	although	SCONJ
ajst-21781	31	2	crisaborole	crisaborole	PROPN
ajst-21781	31	3	has	have	AUX
ajst-21781	31	4	been	be	AUX
ajst-21781	31	5	shown	show	VERB
ajst-21781	31	6	to	to	PART
ajst-21781	31	7	have	have	VERB
ajst-21781	31	8	anti	anti	ADJ
ajst-21781	31	9	-	-	ADJ
ajst-21781	31	10	inflammatory	inflammatory	ADJ
ajst-21781	31	11	effects	effect	NOUN
ajst-21781	31	12	in	in	ADP
ajst-21781	31	13	in	in	ADP
ajst-21781	31	14	vivo	vivo	NOUN
ajst-21781	31	15	,	,	PUNCT
ajst-21781	31	16	in	in	ADP
ajst-21781	31	17	vitro	vitro	X
ajst-21781	31	18	animal	animal	NOUN
ajst-21781	31	19	and	and	CCONJ
ajst-21781	31	20	cellular	cellular	ADJ
ajst-21781	31	21	studies[16	studies[16	NOUN
ajst-21781	31	22	]	]	PUNCT
ajst-21781	31	23	.	.	PUNCT
ajst-21781	32	1	however	however	ADV
ajst-21781	32	2	,	,	PUNCT
ajst-21781	32	3	in	in	ADP
ajst-21781	32	4	clinical	clinical	ADJ
ajst-21781	32	5	trials	trial	NOUN
ajst-21781	32	6	,	,	PUNCT
ajst-21781	32	7	topical	topical	ADJ
ajst-21781	32	8	application	application	NOUN
ajst-21781	32	9	of	of	ADP
ajst-21781	32	10	2	2	NUM
ajst-21781	32	11	%	%	NOUN
ajst-21781	32	12	crisaborole	crisaborole	NOUN
ajst-21781	32	13	twice	twice	ADV
ajst-21781	32	14	daily	daily	ADV
ajst-21781	32	15	was	be	AUX
ajst-21781	32	16	found	find	VERB
ajst-21781	32	17	to	to	PART
ajst-21781	32	18	be	be	AUX
ajst-21781	32	19	the	the	DET
ajst-21781	32	20	most	most	ADV
ajst-21781	32	21	effective	effective	ADJ
ajst-21781	32	22	in	in	ADP
ajst-21781	32	23	controlling	control	VERB
ajst-21781	32	24	the	the	DET
ajst-21781	32	25	condition	condition	NOUN
ajst-21781	32	26	of	of	ADP
ajst-21781	32	27	ad	ad	NOUN
ajst-21781	32	28	and	and	CCONJ
ajst-21781	32	29	improving	improve	VERB
ajst-21781	32	30	itching	itching	NOUN
ajst-21781	32	31	compared	compare	VERB
ajst-21781	32	32	with	with	ADP
ajst-21781	32	33	the	the	DET
ajst-21781	32	34	control	control	NOUN
ajst-21781	32	35	group[16	group[16	PROPN
ajst-21781	32	36	]	]	PUNCT
ajst-21781	32	37	.	.	PUNCT
ajst-21781	33	1	167	167	NUM
ajst-21781	33	2	other	other	ADJ
ajst-21781	33	3	drugs	drug	NOUN
ajst-21781	33	4	(	(	PUNCT
ajst-21781	33	5	e6005	e6005	PROPN
ajst-21781	33	6	,	,	PUNCT
ajst-21781	33	7	gw842470xopa-15406	gw842470xopa-15406	ADJ
ajst-21781	33	8	,	,	PUNCT
ajst-21781	33	9	apremilast	apremilast	ADJ
ajst-21781	33	10	)	)	PUNCT
ajst-21781	33	11	are	be	AUX
ajst-21781	33	12	currently	currently	ADV
ajst-21781	33	13	being	be	AUX
ajst-21781	33	14	investigated	investigate	VERB
ajst-21781	33	15	for	for	ADP
ajst-21781	33	16	the	the	DET
ajst-21781	33	17	treatment	treatment	NOUN
ajst-21781	33	18	of	of	ADP
ajst-21781	33	19	ad[8	ad[8	PROPN
ajst-21781	33	20	]	]	PUNCT
ajst-21781	33	21	.	.	PUNCT
ajst-21781	34	1	4	4	X
ajst-21781	34	2	.	.	X
ajst-21781	34	3	pde-4	pde-4	NOUN
ajst-21781	34	4	inhibitors	inhibitor	NOUN
ajst-21781	34	5	and	and	CCONJ
ajst-21781	34	6	psoriasis	psoriasis	NOUN
ajst-21781	34	7	psoriasis	psoriasis	NOUN
ajst-21781	34	8	is	be	AUX
ajst-21781	34	9	a	a	DET
ajst-21781	34	10	relatively	relatively	ADV
ajst-21781	34	11	common	common	ADJ
ajst-21781	34	12	chronic	chronic	ADJ
ajst-21781	34	13	inflammatory	inflammatory	ADJ
ajst-21781	34	14	skin	skin	NOUN
ajst-21781	34	15	disease	disease	NOUN
ajst-21781	34	16	that	that	PRON
ajst-21781	34	17	mainly	mainly	ADV
ajst-21781	34	18	affects	affect	VERB
ajst-21781	34	19	the	the	DET
ajst-21781	34	20	skin	skin	NOUN
ajst-21781	34	21	,	,	PUNCT
ajst-21781	34	22	nails	nail	NOUN
ajst-21781	34	23	and	and	CCONJ
ajst-21781	34	24	joints[8	joints[8	PROPN
ajst-21781	34	25	]	]	X
ajst-21781	34	26	.	.	PUNCT
ajst-21781	35	1	mild	mild	ADJ
ajst-21781	35	2	psoriasis	psoriasis	NOUN
ajst-21781	35	3	is	be	AUX
ajst-21781	35	4	treated	treat	VERB
ajst-21781	35	5	with	with	ADP
ajst-21781	35	6	principles	principle	NOUN
ajst-21781	35	7	similar	similar	ADJ
ajst-21781	35	8	to	to	ADP
ajst-21781	35	9	those	those	PRON
ajst-21781	35	10	used	use	VERB
ajst-21781	35	11	for	for	ADP
ajst-21781	35	12	ad	ad	NOUN
ajst-21781	35	13	,	,	PUNCT
ajst-21781	35	14	such	such	ADJ
ajst-21781	35	15	as	as	ADP
ajst-21781	35	16	topical	topical	ADJ
ajst-21781	35	17	steroids	steroid	NOUN
ajst-21781	35	18	,	,	PUNCT
ajst-21781	35	19	tcis	tcis	NOUN
ajst-21781	35	20	and	and	CCONJ
ajst-21781	35	21	vitamin	vitamin	NOUN
ajst-21781	35	22	d	d	NOUN
ajst-21781	35	23	analogues	analogue	NOUN
ajst-21781	35	24	;	;	PUNCT
ajst-21781	35	25	psoriasis	psoriasis	NOUN
ajst-21781	35	26	may	may	AUX
ajst-21781	35	27	be	be	AUX
ajst-21781	35	28	associated	associate	VERB
ajst-21781	35	29	with	with	ADP
ajst-21781	35	30	arthritis	arthritis	NOUN
ajst-21781	35	31	,	,	PUNCT
ajst-21781	35	32	synovitis	synovitis	VERB
ajst-21781	35	33	and	and	CCONJ
ajst-21781	35	34	may	may	AUX
ajst-21781	35	35	affect	affect	VERB
ajst-21781	35	36	up	up	ADP
ajst-21781	35	37	to	to	PART
ajst-21781	35	38	30	30	NUM
ajst-21781	35	39	%	%	NOUN
ajst-21781	35	40	of	of	ADP
ajst-21781	35	41	psoriasis	psoriasis	NOUN
ajst-21781	35	42	patients[2,4	patients[2,4	PROPN
ajst-21781	35	43	]	]	PUNCT
ajst-21781	35	44	.	.	PUNCT
ajst-21781	36	1	in	in	ADP
ajst-21781	36	2	the	the	DET
ajst-21781	36	3	skin	skin	NOUN
ajst-21781	36	4	,	,	PUNCT
ajst-21781	36	5	pde4	pde4	NOUN
ajst-21781	36	6	is	be	AUX
ajst-21781	36	7	predominantly	predominantly	ADV
ajst-21781	36	8	expressed	express	VERB
ajst-21781	36	9	in	in	ADP
ajst-21781	36	10	langerhans	langerhans	ADJ
ajst-21781	36	11	cells	cell	NOUN
ajst-21781	36	12	,	,	PUNCT
ajst-21781	36	13	neutrophils	neutrophil	NOUN
ajst-21781	36	14	,	,	PUNCT
ajst-21781	36	15	keratinocytes	keratinocyte	NOUN
ajst-21781	36	16	and	and	CCONJ
ajst-21781	36	17	t	t	NOUN
ajst-21781	36	18	cells	cell	NOUN
ajst-21781	36	19	,	,	PUNCT
ajst-21781	36	20	which	which	PRON
ajst-21781	36	21	are	be	AUX
ajst-21781	36	22	intimately	intimately	ADV
ajst-21781	36	23	involved	involve	VERB
ajst-21781	36	24	in	in	ADP
ajst-21781	36	25	plaque	plaque	NOUN
ajst-21781	36	26	formation	formation	NOUN
ajst-21781	36	27	,	,	PUNCT
ajst-21781	36	28	and	and	CCONJ
ajst-21781	36	29	mrna	mrna	PROPN
ajst-21781	36	30	levels	level	NOUN
ajst-21781	36	31	of	of	ADP
ajst-21781	36	32	pde-4	pde-4	NOUN
ajst-21781	36	33	are	be	AUX
ajst-21781	36	34	significantly	significantly	ADV
ajst-21781	36	35	higher	high	ADJ
ajst-21781	36	36	than	than	ADP
ajst-21781	36	37	in	in	ADP
ajst-21781	36	38	healthy	healthy	ADJ
ajst-21781	36	39	controls[5,6,17	controls[5,6,17	NOUN
ajst-21781	36	40	]	]	PUNCT
ajst-21781	36	41	.	.	PUNCT
ajst-21781	37	1	apremilast	apremilast	ADJ
ajst-21781	37	2	,	,	PUNCT
ajst-21781	37	3	an	an	DET
ajst-21781	37	4	oral	oral	ADJ
ajst-21781	37	5	form	form	NOUN
ajst-21781	37	6	of	of	ADP
ajst-21781	37	7	the	the	DET
ajst-21781	37	8	pde-4	pde-4	ADJ
ajst-21781	37	9	inhibitor	inhibitor	NOUN
ajst-21781	37	10	,	,	PUNCT
ajst-21781	37	11	was	be	AUX
ajst-21781	37	12	approved	approve	VERB
ajst-21781	37	13	in	in	ADP
ajst-21781	37	14	2014	2014	NUM
ajst-21781	37	15	for	for	ADP
ajst-21781	37	16	the	the	DET
ajst-21781	37	17	treatment	treatment	NOUN
ajst-21781	37	18	of	of	ADP
ajst-21781	37	19	psoriatic	psoriatic	ADJ
ajst-21781	37	20	arthritis	arthritis	NOUN
ajst-21781	37	21	and	and	CCONJ
ajst-21781	37	22	plaque	plaque	NOUN
ajst-21781	37	23	psoriasis[8,18	psoriasis[8,18	PROPN
ajst-21781	37	24	]	]	PUNCT
ajst-21781	37	25	.	.	PUNCT
ajst-21781	38	1	oral	oral	ADJ
ajst-21781	38	2	apremilast	apremilast	NOUN
ajst-21781	38	3	was	be	AUX
ajst-21781	38	4	shown	show	VERB
ajst-21781	38	5	in	in	ADP
ajst-21781	38	6	in	in	ADP
ajst-21781	38	7	vivo	vivo	ADJ
ajst-21781	38	8	studies	study	NOUN
ajst-21781	38	9	to	to	PART
ajst-21781	38	10	be	be	AUX
ajst-21781	38	11	effective	effective	ADJ
ajst-21781	38	12	in	in	ADP
ajst-21781	38	13	improving	improve	VERB
ajst-21781	38	14	psoriasis	psoriasis	NOUN
ajst-21781	38	15	lesion	lesion	NOUN
ajst-21781	38	16	thickness	thickness	NOUN
ajst-21781	38	17	and	and	CCONJ
ajst-21781	38	18	levels	level	NOUN
ajst-21781	38	19	of	of	ADP
ajst-21781	38	20	the	the	DET
ajst-21781	38	21	local	local	ADJ
ajst-21781	38	22	inflammatory	inflammatory	ADJ
ajst-21781	38	23	molecules	molecule	NOUN
ajst-21781	38	24	icam-1	icam-1	NOUN
ajst-21781	38	25	,	,	PUNCT
ajst-21781	38	26	hla	hla	PROPN
ajst-21781	38	27	-	-	PUNCT
ajst-21781	38	28	dr	dr	PROPN
ajst-21781	38	29	and	and	CCONJ
ajst-21781	38	30	tnf	tnf	PROPN
ajst-21781	38	31	-	-	PUNCT
ajst-21781	38	32	α[19	α[19	PROPN
ajst-21781	38	33	]	]	PUNCT
ajst-21781	38	34	.	.	PUNCT
ajst-21781	39	1	the	the	DET
ajst-21781	39	2	phase	phase	NOUN
ajst-21781	39	3	iii	iii	NUM
ajst-21781	39	4	study	study	NOUN
ajst-21781	39	5	found	find	VERB
ajst-21781	39	6	that	that	SCONJ
ajst-21781	39	7	33.1	33.1	NUM
ajst-21781	39	8	%	%	NOUN
ajst-21781	39	9	of	of	ADP
ajst-21781	39	10	patients	patient	NOUN
ajst-21781	39	11	with	with	ADP
ajst-21781	39	12	psoriasis	psoriasis	NOUN
ajst-21781	39	13	achieved	achieve	VERB
ajst-21781	39	14	a	a	DET
ajst-21781	39	15	75	75	NUM
ajst-21781	39	16	%	%	NOUN
ajst-21781	39	17	reduction	reduction	NOUN
ajst-21781	39	18	in	in	ADP
ajst-21781	39	19	their	their	PRON
ajst-21781	39	20	baseline	baseline	NOUN
ajst-21781	39	21	psoriasis	psoriasis	NOUN
ajst-21781	39	22	area	area	NOUN
ajst-21781	39	23	and	and	CCONJ
ajst-21781	39	24	severity	severity	NOUN
ajst-21781	39	25	index	index	NOUN
ajst-21781	39	26	(	(	PUNCT
ajst-21781	39	27	pasi-75	pasi-75	PROPN
ajst-21781	39	28	)	)	PUNCT
ajst-21781	39	29	with	with	ADP
ajst-21781	39	30	oral	oral	ADJ
ajst-21781	39	31	apremilast	apremilast	NOUN
ajst-21781	39	32	,	,	PUNCT
ajst-21781	39	33	compared	compare	VERB
ajst-21781	39	34	to	to	ADP
ajst-21781	39	35	5.3	5.3	NUM
ajst-21781	39	36	%	%	NOUN
ajst-21781	39	37	in	in	ADP
ajst-21781	39	38	the	the	DET
ajst-21781	39	39	control	control	NOUN
ajst-21781	39	40	group[20	group[20	NOUN
ajst-21781	39	41	]	]	PUNCT
ajst-21781	39	42	.	.	PUNCT
ajst-21781	40	1	more	more	ADV
ajst-21781	40	2	recently	recently	ADV
ajst-21781	40	3	,	,	PUNCT
ajst-21781	40	4	a	a	DET
ajst-21781	40	5	double	double	ADJ
ajst-21781	40	6	-	-	PUNCT
ajst-21781	40	7	blind	blind	ADJ
ajst-21781	40	8	rct	rct	PROPN
ajst-21781	40	9	(	(	PUNCT
ajst-21781	40	10	n=21	n=21	NOUN
ajst-21781	40	11	)	)	PUNCT
ajst-21781	40	12	found	find	VERB
ajst-21781	40	13	that	that	SCONJ
ajst-21781	40	14	topical	topical	ADJ
ajst-21781	40	15	application	application	NOUN
ajst-21781	40	16	of	of	ADP
ajst-21781	40	17	2	2	NUM
ajst-21781	40	18	%	%	NOUN
ajst-21781	40	19	crisaborole	crisaborole	NOUN
ajst-21781	40	20	was	be	AUX
ajst-21781	40	21	effective	effective	ADJ
ajst-21781	40	22	in	in	ADP
ajst-21781	40	23	controlling	control	VERB
ajst-21781	40	24	the	the	DET
ajst-21781	40	25	disease	disease	NOUN
ajst-21781	40	26	in	in	ADP
ajst-21781	40	27	patients	patient	NOUN
ajst-21781	40	28	with	with	ADP
ajst-21781	40	29	intertriginous	intertriginous	ADJ
ajst-21781	40	30	,	,	PUNCT
ajst-21781	40	31	anogenital	anogenital	ADJ
ajst-21781	40	32	and	and	CCONJ
ajst-21781	40	33	facial	facial	ADJ
ajst-21781	40	34	psoriasis	psoriasis	NOUN
ajst-21781	40	35	,	,	PUNCT
ajst-21781	40	36	and	and	CCONJ
ajst-21781	40	37	no	no	DET
ajst-21781	40	38	adverse	adverse	ADJ
ajst-21781	40	39	events	event	NOUN
ajst-21781	40	40	were	be	AUX
ajst-21781	40	41	reported[18	reported[18	NOUN
ajst-21781	40	42	]	]	PUNCT
ajst-21781	40	43	.	.	PUNCT
ajst-21781	41	1	in	in	ADP
ajst-21781	41	2	addition	addition	NOUN
ajst-21781	41	3	,	,	PUNCT
ajst-21781	41	4	successful	successful	ADJ
ajst-21781	41	5	case	case	NOUN
ajst-21781	41	6	reports	report	NOUN
ajst-21781	41	7	of	of	ADP
ajst-21781	41	8	the	the	DET
ajst-21781	41	9	use	use	NOUN
ajst-21781	41	10	of	of	ADP
ajst-21781	41	11	2	2	NUM
ajst-21781	41	12	%	%	NOUN
ajst-21781	41	13	crisaborole	crisaborole	NOUN
ajst-21781	41	14	in	in	ADP
ajst-21781	41	15	the	the	DET
ajst-21781	41	16	treatment	treatment	NOUN
ajst-21781	41	17	of	of	ADP
ajst-21781	41	18	facial	facial	ADJ
ajst-21781	41	19	,	,	PUNCT
ajst-21781	41	20	groin	groin	NOUN
ajst-21781	41	21	and	and	CCONJ
ajst-21781	41	22	inframammary	inframammary	ADJ
ajst-21781	41	23	psoriasis	psoriasis	NOUN
ajst-21781	41	24	have	have	AUX
ajst-21781	41	25	been	be	AUX
ajst-21781	41	26	reported[6,18	reported[6,18	PROPN
ajst-21781	41	27	]	]	PUNCT
ajst-21781	41	28	.	.	PUNCT
ajst-21781	42	1	therefore	therefore	ADV
ajst-21781	42	2	,	,	PUNCT
ajst-21781	42	3	topical	topical	ADJ
ajst-21781	42	4	crisaborole	crisaborole	NOUN
ajst-21781	42	5	may	may	AUX
ajst-21781	42	6	also	also	ADV
ajst-21781	42	7	be	be	AUX
ajst-21781	42	8	a	a	DET
ajst-21781	42	9	non	non	ADJ
ajst-21781	42	10	-	-	ADJ
ajst-21781	42	11	steroidal	steroidal	ADJ
ajst-21781	42	12	choice	choice	NOUN
ajst-21781	42	13	for	for	ADP
ajst-21781	42	14	the	the	DET
ajst-21781	42	15	treatment	treatment	NOUN
ajst-21781	42	16	of	of	ADP
ajst-21781	42	17	psoriasis	psoriasis	NOUN
ajst-21781	42	18	.	.	PUNCT
ajst-21781	43	1	5	5	X
ajst-21781	43	2	.	.	X
ajst-21781	43	3	pde-4	pde-4	NOUN
ajst-21781	43	4	inhibitors	inhibitor	NOUN
ajst-21781	43	5	and	and	CCONJ
ajst-21781	43	6	vitiligo	vitiligo	NOUN
ajst-21781	43	7	vitiligo	vitiligo	NOUN
ajst-21781	43	8	is	be	AUX
ajst-21781	43	9	a	a	DET
ajst-21781	43	10	chronic	chronic	ADJ
ajst-21781	43	11	autoimmune	autoimmune	ADJ
ajst-21781	43	12	skin	skin	NOUN
ajst-21781	43	13	disease	disease	NOUN
ajst-21781	43	14	with	with	ADP
ajst-21781	43	15	a	a	DET
ajst-21781	43	16	complex	complex	ADJ
ajst-21781	43	17	pathogenesis	pathogenesis	NOUN
ajst-21781	43	18	and	and	CCONJ
ajst-21781	43	19	a	a	DET
ajst-21781	43	20	prevalence	prevalence	NOUN
ajst-21781	43	21	of	of	ADP
ajst-21781	43	22	about	about	ADV
ajst-21781	43	23	0.5	0.5	NUM
ajst-21781	43	24	-	-	PUNCT
ajst-21781	43	25	2%[21	2%[21	NUM
ajst-21781	43	26	]	]	PUNCT
ajst-21781	43	27	.	.	PUNCT
ajst-21781	44	1	pde-4	pde-4	NOUN
ajst-21781	44	2	inhibitors	inhibitor	NOUN
ajst-21781	44	3	can	can	AUX
ajst-21781	44	4	promote	promote	VERB
ajst-21781	44	5	mitf	mitf	ADJ
ajst-21781	44	6	expression	expression	NOUN
ajst-21781	44	7	by	by	ADP
ajst-21781	44	8	inhibiting	inhibit	VERB
ajst-21781	44	9	c	c	NOUN
ajst-21781	44	10	-	-	PUNCT
ajst-21781	44	11	amp	amp	NOUN
ajst-21781	44	12	hydrolysis.mitf	hydrolysis.mitf	PROPN
ajst-21781	44	13	can	can	AUX
ajst-21781	44	14	further	far	ADV
ajst-21781	44	15	induce	induce	VERB
ajst-21781	44	16	the	the	DET
ajst-21781	44	17	transcription	transcription	NOUN
ajst-21781	44	18	and	and	CCONJ
ajst-21781	44	19	synthesis	synthesis	NOUN
ajst-21781	44	20	of	of	ADP
ajst-21781	44	21	tyr	tyr	PROPN
ajst-21781	44	22	and	and	CCONJ
ajst-21781	44	23	tyrp2	tyrp2	PROPN
ajst-21781	44	24	,	,	PUNCT
ajst-21781	44	25	thereby	thereby	ADV
ajst-21781	44	26	enhancing	enhance	VERB
ajst-21781	44	27	melanocyte	melanocyte	NOUN
ajst-21781	44	28	proliferation	proliferation	NOUN
ajst-21781	44	29	and	and	CCONJ
ajst-21781	44	30	melanogenesis[7	melanogenesis[7	NOUN
ajst-21781	44	31	]	]	X
ajst-21781	44	32	.	.	PUNCT
ajst-21781	45	1	pde-4	pde-4	NOUN
ajst-21781	45	2	inhibitors	inhibitor	NOUN
ajst-21781	45	3	can	can	AUX
ajst-21781	45	4	effectively	effectively	ADV
ajst-21781	45	5	block	block	VERB
ajst-21781	45	6	ifn	ifn	PROPN
ajst-21781	45	7	-	-	PUNCT
ajst-21781	45	8	γ	γ	NOUN
ajst-21781	45	9	-	-	ADJ
ajst-21781	45	10	induced	induce	VERB
ajst-21781	45	11	cd8	cd8	PROPN
ajst-21781	45	12	+	+	PROPN
ajst-21781	45	13	t	t	PROPN
ajst-21781	45	14	lymphocyte	lymphocyte	ADJ
ajst-21781	45	15	recruitment	recruitment	NOUN
ajst-21781	45	16	to	to	ADP
ajst-21781	45	17	the	the	DET
ajst-21781	45	18	skin	skin	NOUN
ajst-21781	45	19	and	and	CCONJ
ajst-21781	45	20	control	control	NOUN
ajst-21781	45	21	disease	disease	NOUN
ajst-21781	45	22	progression[22	progression[22	NOUN
ajst-21781	45	23	]	]	PUNCT
ajst-21781	45	24	.	.	PUNCT
ajst-21781	46	1	the	the	DET
ajst-21781	46	2	possible	possible	ADJ
ajst-21781	46	3	mechanism	mechanism	NOUN
ajst-21781	46	4	is	be	AUX
ajst-21781	46	5	that	that	SCONJ
ajst-21781	46	6	the	the	DET
ajst-21781	46	7	statjak	statjak	ADJ
ajst-21781	46	8	pathway	pathway	NOUN
ajst-21781	46	9	of	of	ADP
ajst-21781	46	10	cd8	cd8	PROPN
ajst-21781	46	11	+	+	PROPN
ajst-21781	46	12	t	t	PROPN
ajst-21781	46	13	lymphocytes	lymphocyte	NOUN
ajst-21781	46	14	interacts	interact	VERB
ajst-21781	46	15	with	with	ADP
ajst-21781	46	16	cxc	cxc	PROPN
ajst-21781	46	17	chemokine	chemokine	PROPN
ajst-21781	46	18	ligand	ligand	PROPN
ajst-21781	46	19	9	9	NUM
ajst-21781	46	20	(	(	PUNCT
ajst-21781	46	21	cxcl9	cxcl9	NOUN
ajst-21781	46	22	)	)	PUNCT
ajst-21781	46	23	and	and	CCONJ
ajst-21781	46	24	cxcl10	cxcl10	NOUN
ajst-21781	46	25	of	of	ADP
ajst-21781	46	26	local	local	ADJ
ajst-21781	46	27	keratinocytes	keratinocyte	NOUN
ajst-21781	46	28	in	in	ADP
ajst-21781	46	29	the	the	DET
ajst-21781	46	30	skin	skin	NOUN
ajst-21781	46	31	and	and	CCONJ
ajst-21781	46	32	positively	positively	ADV
ajst-21781	46	33	recruits	recruit	VERB
ajst-21781	46	34	cd8	cd8	PROPN
ajst-21781	46	35	+	+	PROPN
ajst-21781	46	36	t	t	PROPN
ajst-21781	46	37	lymphocytes	lymphocyte	VERB
ajst-21781	46	38	to	to	PART
ajst-21781	46	39	target	target	VERB
ajst-21781	46	40	melanocytes[23	melanocytes[23	NOUN
ajst-21781	46	41	]	]	PUNCT
ajst-21781	46	42	.	.	PUNCT
ajst-21781	47	1	pde-4	pde-4	X
ajst-21781	47	2	inhibitors	inhibitor	NOUN
ajst-21781	47	3	also	also	ADV
ajst-21781	47	4	induced	induce	VERB
ajst-21781	47	5	increased	increase	VERB
ajst-21781	47	6	levels	level	NOUN
ajst-21781	47	7	of	of	ADP
ajst-21781	47	8	camp	camp	NOUN
ajst-21781	47	9	in	in	ADP
ajst-21781	47	10	th17	th17	PROPN
ajst-21781	47	11	lymphocytes	lymphocyte	NOUN
ajst-21781	47	12	,	,	PUNCT
ajst-21781	47	13	which	which	PRON
ajst-21781	47	14	in	in	ADP
ajst-21781	47	15	turn	turn	NOUN
ajst-21781	47	16	inhibited	inhibit	VERB
ajst-21781	47	17	its	its	PRON
ajst-21781	47	18	activity	activity	NOUN
ajst-21781	47	19	,	,	PUNCT
ajst-21781	47	20	thus	thus	ADV
ajst-21781	47	21	avoiding	avoid	VERB
ajst-21781	47	22	inhibition	inhibition	NOUN
ajst-21781	47	23	of	of	ADP
ajst-21781	47	24	the	the	DET
ajst-21781	47	25	mitf	mitf	NOUN
ajst-21781	47	26	pathway[24	pathway[24	NOUN
ajst-21781	47	27	]	]	PUNCT
ajst-21781	47	28	.	.	PUNCT
ajst-21781	48	1	majid	majid	PROPN
ajst-21781	48	2	et	et	PROPN
ajst-21781	48	3	al	al	PROPN
ajst-21781	48	4	.	.	PROPN
ajst-21781	48	5	found	find	VERB
ajst-21781	48	6	that	that	SCONJ
ajst-21781	48	7	when	when	SCONJ
ajst-21781	48	8	adult	adult	NOUN
ajst-21781	48	9	patients	patient	NOUN
ajst-21781	48	10	(	(	PUNCT
ajst-21781	48	11	n=13	n=13	PROPN
ajst-21781	48	12	)	)	PUNCT
ajst-21781	48	13	with	with	ADP
ajst-21781	48	14	non	non	ADJ
ajst-21781	48	15	-	-	ADJ
ajst-21781	48	16	segmental	segmental	ADJ
ajst-21781	48	17	vitiligo	vitiligo	NOUN
ajst-21781	48	18	(	(	PUNCT
ajst-21781	48	19	4%-30	4%-30	NUM
ajst-21781	48	20	%	%	NOUN
ajst-21781	48	21	of	of	ADP
ajst-21781	48	22	affected	affected	ADJ
ajst-21781	48	23	area	area	NOUN
ajst-21781	48	24	)	)	PUNCT
ajst-21781	48	25	were	be	AUX
ajst-21781	48	26	treated	treat	VERB
ajst-21781	48	27	with	with	ADP
ajst-21781	48	28	apremilast	apremilast	NOUN
ajst-21781	48	29	30	30	NUM
ajst-21781	48	30	mg	mg	NUM
ajst-21781	48	31	/	/	SYM
ajst-21781	48	32	dose	dose	NOUN
ajst-21781	48	33	orally	orally	ADV
ajst-21781	48	34	twice	twice	DET
ajst-21781	48	35	a	a	DET
ajst-21781	48	36	day	day	NOUN
ajst-21781	48	37	for	for	ADP
ajst-21781	48	38	3	3	NUM
ajst-21781	48	39	months	month	NOUN
ajst-21781	48	40	,	,	PUNCT
ajst-21781	48	41	8	8	NUM
ajst-21781	48	42	cases	case	NOUN
ajst-21781	48	43	(	(	PUNCT
ajst-21781	48	44	61.5	61.5	NUM
ajst-21781	48	45	%	%	NOUN
ajst-21781	48	46	)	)	PUNCT
ajst-21781	48	47	showed	show	VERB
ajst-21781	48	48	hyperpigmentation	hyperpigmentation	NOUN
ajst-21781	48	49	of	of	ADP
ajst-21781	48	50	the	the	DET
ajst-21781	48	51	face	face	NOUN
ajst-21781	48	52	,	,	PUNCT
ajst-21781	48	53	neck	neck	NOUN
ajst-21781	48	54	,	,	PUNCT
ajst-21781	48	55	trunk	trunk	NOUN
ajst-21781	48	56	and	and	CCONJ
ajst-21781	48	57	hands	hand	NOUN
ajst-21781	48	58	,	,	PUNCT
ajst-21781	48	59	with	with	ADP
ajst-21781	48	60	a	a	DET
ajst-21781	48	61	mean	mean	ADJ
ajst-21781	48	62	reduction	reduction	NOUN
ajst-21781	48	63	in	in	ADP
ajst-21781	48	64	vasi	vasi	PROPN
ajst-21781	48	65	of	of	ADP
ajst-21781	48	66	7.11	7.11	NUM
ajst-21781	48	67	%	%	NOUN
ajst-21781	48	68	,	,	PUNCT
ajst-21781	48	69	and	and	CCONJ
ajst-21781	48	70	there	there	PRON
ajst-21781	48	71	was	be	VERB
ajst-21781	48	72	no	no	DET
ajst-21781	48	73	increase	increase	NOUN
ajst-21781	48	74	in	in	ADP
ajst-21781	48	75	vasi	vasi	PROPN
ajst-21781	48	76	in	in	ADP
ajst-21781	48	77	any	any	PRON
ajst-21781	48	78	of	of	ADP
ajst-21781	48	79	the	the	DET
ajst-21781	48	80	patients	patient	NOUN
ajst-21781	48	81	enrolled[22,24	enrolled[22,24	VERB
ajst-21781	48	82	]	]	PUNCT
ajst-21781	48	83	.	.	PUNCT
ajst-21781	49	1	tam	tam	PROPN
ajst-21781	49	2	et	et	PROPN
ajst-21781	49	3	al	al	PROPN
ajst-21781	49	4	.	.	PROPN
ajst-21781	49	5	reported	report	VERB
ajst-21781	49	6	a	a	DET
ajst-21781	49	7	case	case	NOUN
ajst-21781	49	8	of	of	ADP
ajst-21781	49	9	a	a	DET
ajst-21781	49	10	71	71	NUM
ajst-21781	49	11	-	-	PUNCT
ajst-21781	49	12	year	year	NOUN
ajst-21781	49	13	-	-	PUNCT
ajst-21781	49	14	old	old	ADJ
ajst-21781	49	15	male	male	ADJ
ajst-21781	49	16	patient	patient	NOUN
ajst-21781	49	17	with	with	ADP
ajst-21781	49	18	vitiligo	vitiligo	NOUN
ajst-21781	49	19	with	with	ADP
ajst-21781	49	20	lesions	lesion	NOUN
ajst-21781	49	21	on	on	ADP
ajst-21781	49	22	the	the	DET
ajst-21781	49	23	limbs	limb	NOUN
ajst-21781	49	24	and	and	CCONJ
ajst-21781	49	25	trunk	trunk	NOUN
ajst-21781	49	26	involving	involve	VERB
ajst-21781	49	27	10	10	NUM
ajst-21781	49	28	%	%	NOUN
ajst-21781	49	29	of	of	ADP
ajst-21781	49	30	the	the	DET
ajst-21781	49	31	body	body	NOUN
ajst-21781	49	32	surface	surface	NOUN
ajst-21781	49	33	area	area	NOUN
ajst-21781	49	34	(	(	PUNCT
ajst-21781	49	35	bsa	bsa	PROPN
ajst-21781	49	36	)	)	PUNCT
ajst-21781	49	37	,	,	PUNCT
ajst-21781	49	38	history	history	NOUN
ajst-21781	49	39	of	of	ADP
ajst-21781	49	40	atopic	atopic	NOUN
ajst-21781	49	41	dermatitis	dermatitis	NOUN
ajst-21781	49	42	and	and	CCONJ
ajst-21781	49	43	ineffective	ineffective	ADJ
ajst-21781	49	44	conventional	conventional	ADJ
ajst-21781	49	45	treatment	treatment	NOUN
ajst-21781	49	46	,	,	PUNCT
ajst-21781	49	47	who	who	PRON
ajst-21781	49	48	was	be	AUX
ajst-21781	49	49	treated	treat	VERB
ajst-21781	49	50	with	with	ADP
ajst-21781	49	51	crisaborole	crisaborole	NOUN
ajst-21781	49	52	ointment	ointment	NOUN
ajst-21781	49	53	,	,	PUNCT
ajst-21781	49	54	and	and	CCONJ
ajst-21781	49	55	after	after	ADP
ajst-21781	49	56	10	10	NUM
ajst-21781	49	57	months	month	NOUN
ajst-21781	49	58	of	of	ADP
ajst-21781	49	59	use	use	NOUN
ajst-21781	49	60	,	,	PUNCT
ajst-21781	49	61	vitiligo	vitiligo	ADJ
ajst-21781	49	62	hyperpigmentation	hyperpigmentation	NOUN
ajst-21781	49	63	was	be	AUX
ajst-21781	49	64	evident	evident	ADJ
ajst-21781	49	65	on	on	ADP
ajst-21781	49	66	the	the	DET
ajst-21781	49	67	trunk	trunk	NOUN
ajst-21781	49	68	,	,	PUNCT
ajst-21781	49	69	and	and	CCONJ
ajst-21781	49	70	after	after	ADP
ajst-21781	49	71	22	22	NUM
ajst-21781	49	72	months	month	NOUN
ajst-21781	49	73	,	,	PUNCT
ajst-21781	49	74	the	the	DET
ajst-21781	49	75	dorsal	dorsal	NOUN
ajst-21781	49	76	side	side	NOUN
ajst-21781	49	77	of	of	ADP
ajst-21781	49	78	the	the	DET
ajst-21781	49	79	hands	hand	NOUN
ajst-21781	49	80	was	be	AUX
ajst-21781	49	81	significantly	significantly	ADV
ajst-21781	49	82	hyperpigmented	hyperpigmente	VERB
ajst-21781	49	83	and	and	CCONJ
ajst-21781	49	84	no	no	ADV
ajst-21781	49	85	longer	long	ADV
ajst-21781	49	86	developing[7,23	developing[7,23	PROPN
ajst-21781	49	87	]	]	PUNCT
ajst-21781	49	88	.	.	PUNCT
ajst-21781	50	1	tausend	tausend	AUX
ajst-21781	50	2	et	et	PROPN
ajst-21781	50	3	al	al	PROPN
ajst-21781	50	4	.	.	PROPN
ajst-21781	50	5	reported	report	VERB
ajst-21781	50	6	a	a	DET
ajst-21781	50	7	case	case	NOUN
ajst-21781	50	8	of	of	ADP
ajst-21781	50	9	a	a	DET
ajst-21781	50	10	40	40	NUM
ajst-21781	50	11	-	-	PUNCT
ajst-21781	50	12	year	year	NOUN
ajst-21781	50	13	-	-	PUNCT
ajst-21781	50	14	old	old	ADJ
ajst-21781	50	15	man	man	NOUN
ajst-21781	50	16	with	with	ADP
ajst-21781	50	17	hypopigmented	hypopigmented	ADJ
ajst-21781	50	18	patches	patch	NOUN
ajst-21781	50	19	on	on	ADP
ajst-21781	50	20	his	his	PRON
ajst-21781	50	21	ears	ear	NOUN
ajst-21781	50	22	and	and	CCONJ
ajst-21781	50	23	penis	penis	NOUN
ajst-21781	50	24	for	for	ADP
ajst-21781	50	25	20	20	NUM
ajst-21781	50	26	years	year	NOUN
ajst-21781	50	27	,	,	PUNCT
ajst-21781	50	28	who	who	PRON
ajst-21781	50	29	was	be	AUX
ajst-21781	50	30	treated	treat	VERB
ajst-21781	50	31	with	with	ADP
ajst-21781	50	32	crisaborole	crisaborole	PROPN
ajst-21781	50	33	ointment	ointment	NOUN
ajst-21781	50	34	twice	twice	DET
ajst-21781	50	35	a	a	DET
ajst-21781	50	36	day	day	NOUN
ajst-21781	50	37	externally	externally	ADV
ajst-21781	50	38	on	on	ADP
ajst-21781	50	39	the	the	DET
ajst-21781	50	40	ears	ear	NOUN
ajst-21781	50	41	and	and	CCONJ
ajst-21781	50	42	no	no	DET
ajst-21781	50	43	medication	medication	NOUN
ajst-21781	50	44	on	on	ADP
ajst-21781	50	45	the	the	DET
ajst-21781	50	46	penis	penis	NOUN
ajst-21781	50	47	,	,	PUNCT
ajst-21781	50	48	and	and	CCONJ
ajst-21781	50	49	after	after	ADP
ajst-21781	50	50	1	1	NUM
ajst-21781	50	51	month	month	NOUN
ajst-21781	50	52	there	there	PRON
ajst-21781	50	53	was	be	VERB
ajst-21781	50	54	significant	significant	ADJ
ajst-21781	50	55	pigmentation	pigmentation	NOUN
ajst-21781	50	56	on	on	ADP
ajst-21781	50	57	the	the	DET
ajst-21781	50	58	ears	ear	NOUN
ajst-21781	50	59	and	and	CCONJ
ajst-21781	50	60	no	no	DET
ajst-21781	50	61	significant	significant	ADJ
ajst-21781	50	62	change	change	NOUN
ajst-21781	50	63	on	on	ADP
ajst-21781	50	64	the	the	DET
ajst-21781	50	65	unmedicated	unmedicated	ADJ
ajst-21781	50	66	penis[22	penis[22	NOUN
ajst-21781	50	67	]	]	X
ajst-21781	50	68	.	.	PUNCT
ajst-21781	51	1	6	6	NUM
ajst-21781	51	2	.	.	X
ajst-21781	51	3	pde-4	pde-4	NOUN
ajst-21781	51	4	inhibitors	inhibitor	NOUN
ajst-21781	51	5	and	and	CCONJ
ajst-21781	51	6	lupus	lupus	NOUN
ajst-21781	51	7	systemic	systemic	ADJ
ajst-21781	51	8	lupus	lupus	NOUN
ajst-21781	51	9	erythematosus	erythematosus	NOUN
ajst-21781	51	10	(	(	PUNCT
ajst-21781	51	11	sle	sle	PROPN
ajst-21781	51	12	)	)	PUNCT
ajst-21781	51	13	is	be	AUX
ajst-21781	51	14	a	a	DET
ajst-21781	51	15	complex	complex	ADJ
ajst-21781	51	16	autoimmune	autoimmune	ADJ
ajst-21781	51	17	disease	disease	NOUN
ajst-21781	51	18	that	that	PRON
ajst-21781	51	19	can	can	AUX
ajst-21781	51	20	affect	affect	VERB
ajst-21781	51	21	multiple	multiple	ADJ
ajst-21781	51	22	systemic	systemic	ADJ
ajst-21781	51	23	organs	organ	NOUN
ajst-21781	51	24	,	,	PUNCT
ajst-21781	51	25	including	include	VERB
ajst-21781	51	26	the	the	DET
ajst-21781	51	27	skin	skin	NOUN
ajst-21781	51	28	,	,	PUNCT
ajst-21781	51	29	joints	joint	NOUN
ajst-21781	51	30	,	,	PUNCT
ajst-21781	51	31	kidneys	kidney	NOUN
ajst-21781	51	32	and	and	CCONJ
ajst-21781	51	33	nervous	nervous	ADJ
ajst-21781	51	34	system[2	system[2	NOUN
ajst-21781	51	35	]	]	PUNCT
ajst-21781	51	36	.	.	PUNCT
ajst-21781	52	1	currently	currently	ADV
ajst-21781	52	2	,	,	PUNCT
ajst-21781	52	3	the	the	DET
ajst-21781	52	4	conventional	conventional	ADJ
ajst-21781	52	5	treatment	treatment	NOUN
ajst-21781	52	6	options	option	NOUN
ajst-21781	52	7	for	for	ADP
ajst-21781	52	8	sle	sle	PROPN
ajst-21781	52	9	include	include	VERB
ajst-21781	52	10	antimalarials	antimalarial	NOUN
ajst-21781	52	11	,	,	PUNCT
ajst-21781	52	12	corticosteroids	corticosteroid	NOUN
ajst-21781	52	13	and	and	CCONJ
ajst-21781	52	14	dmards	dmards	ADP
ajst-21781	52	15	such	such	ADJ
ajst-21781	52	16	as	as	ADP
ajst-21781	52	17	methotrexate	methotrexate	NOUN
ajst-21781	52	18	and	and	CCONJ
ajst-21781	52	19	rituximab	rituximab	NOUN
ajst-21781	52	20	,	,	PUNCT
ajst-21781	52	21	and	and	CCONJ
ajst-21781	52	22	pde-4	pde-4	DET
ajst-21781	52	23	inhibitors	inhibitor	NOUN
ajst-21781	52	24	are	be	AUX
ajst-21781	52	25	also	also	ADV
ajst-21781	52	26	expected	expect	VERB
ajst-21781	52	27	to	to	PART
ajst-21781	52	28	be	be	AUX
ajst-21781	52	29	used	use	VERB
ajst-21781	52	30	in	in	ADP
ajst-21781	52	31	the	the	DET
ajst-21781	52	32	treatment	treatment	NOUN
ajst-21781	52	33	of	of	ADP
ajst-21781	52	34	sle	sle	PROPN
ajst-21781	52	35	due	due	ADP
ajst-21781	52	36	to	to	ADP
ajst-21781	52	37	their	their	PRON
ajst-21781	52	38	antiinflammatory	antiinflammatory	NOUN
ajst-21781	52	39	effects[4	effects[4	PROPN
ajst-21781	52	40	]	]	PUNCT
ajst-21781	52	41	.	.	PUNCT
ajst-21781	53	1	apremilast	apremilast	PROPN
ajst-21781	53	2	is	be	AUX
ajst-21781	53	3	currently	currently	ADV
ajst-21781	53	4	in	in	ADP
ajst-21781	53	5	clinical	clinical	ADJ
ajst-21781	53	6	trials	trial	NOUN
ajst-21781	53	7	and	and	CCONJ
ajst-21781	53	8	is	be	AUX
ajst-21781	53	9	expected	expect	VERB
ajst-21781	53	10	to	to	PART
ajst-21781	53	11	become	become	VERB
ajst-21781	53	12	a	a	DET
ajst-21781	53	13	new	new	ADJ
ajst-21781	53	14	treatment	treatment	NOUN
ajst-21781	53	15	option	option	NOUN
ajst-21781	53	16	for	for	ADP
ajst-21781	53	17	sle	sle	NOUN
ajst-21781	53	18	when	when	SCONJ
ajst-21781	53	19	the	the	DET
ajst-21781	53	20	results	result	NOUN
ajst-21781	53	21	are	be	AUX
ajst-21781	53	22	reported.the	reported.the	PRON
ajst-21781	53	23	compound	compound	NOUN
ajst-21781	53	24	ncs613	ncs613	NOUN
ajst-21781	53	25	also	also	ADV
ajst-21781	53	26	showed	show	VERB
ajst-21781	53	27	promising	promising	ADJ
ajst-21781	53	28	results	result	NOUN
ajst-21781	53	29	in	in	ADP
ajst-21781	53	30	the	the	DET
ajst-21781	53	31	treatment	treatment	NOUN
ajst-21781	53	32	of	of	ADP
ajst-21781	53	33	sle	sle	PROPN
ajst-21781	53	34	in	in	ADP
ajst-21781	53	35	mice[9,25	mice[9,25	PROPN
ajst-21781	53	36	]	]	PUNCT
ajst-21781	53	37	.	.	PUNCT
ajst-21781	54	1	the	the	DET
ajst-21781	54	2	possible	possible	ADJ
ajst-21781	54	3	mechanism	mechanism	NOUN
ajst-21781	54	4	is	be	AUX
ajst-21781	54	5	that	that	SCONJ
ajst-21781	54	6	ncs613	ncs613	PROPN
ajst-21781	54	7	may	may	AUX
ajst-21781	54	8	further	far	ADV
ajst-21781	54	9	regulate	regulate	VERB
ajst-21781	54	10	the	the	DET
ajst-21781	54	11	inhibition	inhibition	NOUN
ajst-21781	54	12	of	of	ADP
ajst-21781	54	13	tnf	tnf	PROPN
ajst-21781	54	14	-	-	PUNCT
ajst-21781	54	15	α	α	PROPN
ajst-21781	54	16	,	,	PUNCT
ajst-21781	54	17	il-6	il-6	NOUN
ajst-21781	54	18	and	and	CCONJ
ajst-21781	54	19	il-8	il-8	PUNCT
ajst-21781	54	20	by	by	ADP
ajst-21781	54	21	inhibiting	inhibit	VERB
ajst-21781	54	22	the	the	DET
ajst-21781	54	23	phosphorylation	phosphorylation	NOUN
ajst-21781	54	24	of	of	ADP
ajst-21781	54	25	p38	p38	NOUN
ajst-21781	54	26	mapk	mapk	NOUN
ajst-21781	54	27	and	and	CCONJ
ajst-21781	54	28	the	the	DET
ajst-21781	54	29	nuclear	nuclear	ADJ
ajst-21781	54	30	translocation	translocation	NOUN
ajst-21781	54	31	of	of	ADP
ajst-21781	54	32	nf	nf	NOUN
ajst-21781	54	33	-	-	PUNCT
ajst-21781	54	34	κb[12	κb[12	PROPN
ajst-21781	54	35	]	]	X
ajst-21781	54	36	.	.	PUNCT
ajst-21781	55	1	7	7	X
ajst-21781	55	2	.	.	NOUN
ajst-21781	55	3	pde-4	pde-4	NOUN
ajst-21781	55	4	inhibitors	inhibitor	NOUN
ajst-21781	55	5	and	and	CCONJ
ajst-21781	55	6	seborrheic	seborrheic	VERB
ajst-21781	55	7	dermatitis	dermatitis	NOUN
ajst-21781	55	8	seborrhoeic	seborrhoeic	PROPN
ajst-21781	55	9	dermatitis	dermatitis	NOUN
ajst-21781	55	10	is	be	AUX
ajst-21781	55	11	a	a	DET
ajst-21781	55	12	common	common	ADJ
ajst-21781	55	13	chronic	chronic	ADJ
ajst-21781	55	14	skin	skin	NOUN
ajst-21781	55	15	condition	condition	NOUN
ajst-21781	55	16	that	that	PRON
ajst-21781	55	17	can	can	AUX
ajst-21781	55	18	affect	affect	VERB
ajst-21781	55	19	both	both	DET
ajst-21781	55	20	infants	infant	NOUN
ajst-21781	55	21	and	and	CCONJ
ajst-21781	55	22	adults[26	adults[26	NOUN
ajst-21781	55	23	]	]	PUNCT
ajst-21781	55	24	.	.	PUNCT
ajst-21781	56	1	"	"	PUNCT
ajst-21781	56	2	greasy	greasy	ADJ
ajst-21781	56	3	"	"	PUNCT
ajst-21781	56	4	yellow	yellow	ADJ
ajst-21781	56	5	scales	scale	NOUN
ajst-21781	56	6	and	and	CCONJ
ajst-21781	56	7	erythema	erythema	ADJ
ajst-21781	56	8	are	be	AUX
ajst-21781	56	9	often	often	ADV
ajst-21781	56	10	found	find	VERB
ajst-21781	56	11	in	in	ADP
ajst-21781	56	12	areas	area	NOUN
ajst-21781	56	13	of	of	ADP
ajst-21781	56	14	high	high	ADJ
ajst-21781	56	15	sebum	sebum	NOUN
ajst-21781	56	16	production	production	NOUN
ajst-21781	56	17	(	(	PUNCT
ajst-21781	56	18	scalp	scalp	NOUN
ajst-21781	56	19	,	,	PUNCT
ajst-21781	56	20	eyebrows	eyebrow	NOUN
ajst-21781	56	21	,	,	PUNCT
ajst-21781	56	22	nasolabial	nasolabial	ADJ
ajst-21781	56	23	folds	fold	NOUN
ajst-21781	56	24	,	,	PUNCT
ajst-21781	56	25	chest	chest	NOUN
ajst-21781	56	26	and	and	CCONJ
ajst-21781	56	27	intertriginous	intertriginous	ADJ
ajst-21781	56	28	areas)[26	areas)[26	NOUN
ajst-21781	56	29	]	]	PUNCT
ajst-21781	56	30	.	.	PUNCT
ajst-21781	57	1	the	the	DET
ajst-21781	57	2	exact	exact	ADJ
ajst-21781	57	3	pathogenesis	pathogenesis	NOUN
ajst-21781	57	4	of	of	ADP
ajst-21781	57	5	seborrhoeic	seborrhoeic	PROPN
ajst-21781	57	6	dermatitis	dermatitis	NOUN
ajst-21781	57	7	is	be	AUX
ajst-21781	57	8	unclear	unclear	ADJ
ajst-21781	57	9	and	and	CCONJ
ajst-21781	57	10	may	may	AUX
ajst-21781	57	11	be	be	AUX
ajst-21781	57	12	related	relate	VERB
ajst-21781	57	13	to	to	ADP
ajst-21781	57	14	an	an	DET
ajst-21781	57	15	aberrant	aberrant	ADJ
ajst-21781	57	16	inflammatory	inflammatory	ADJ
ajst-21781	57	17	response	response	NOUN
ajst-21781	57	18	,	,	PUNCT
ajst-21781	57	19	a	a	DET
ajst-21781	57	20	by	by	ADP
ajst-21781	57	21	-	-	PUNCT
ajst-21781	57	22	product	product	NOUN
ajst-21781	57	23	of	of	ADP
ajst-21781	57	24	malassezia	malassezia	NOUN
ajst-21781	57	25	species	specie	NOUN
ajst-21781	57	26	,	,	PUNCT
ajst-21781	57	27	a	a	DET
ajst-21781	57	28	resident	resident	ADJ
ajst-21781	57	29	flora	flora	NOUN
ajst-21781	57	30	of	of	ADP
ajst-21781	57	31	the	the	DET
ajst-21781	57	32	skin[8	skin[8	NOUN
ajst-21781	57	33	]	]	PUNCT
ajst-21781	57	34	.	.	PUNCT
ajst-21781	58	1	topical	topical	ADJ
ajst-21781	58	2	azole	azole	NOUN
ajst-21781	58	3	antifungals	antifungal	NOUN
ajst-21781	58	4	may	may	AUX
ajst-21781	58	5	have	have	VERB
ajst-21781	58	6	a	a	DET
ajst-21781	58	7	therapeutic	therapeutic	ADJ
ajst-21781	58	8	effect	effect	NOUN
ajst-21781	58	9	by	by	ADP
ajst-21781	58	10	inhibiting	inhibit	VERB
ajst-21781	58	11	malassezia	malassezia	NOUN
ajst-21781	58	12	species	specie	NOUN
ajst-21781	58	13	or	or	CCONJ
ajst-21781	58	14	by	by	ADP
ajst-21781	58	15	suppressing	suppress	VERB
ajst-21781	58	16	the	the	DET
ajst-21781	58	17	inflammatory	inflammatory	ADJ
ajst-21781	58	18	response[26	response[26	NOUN
ajst-21781	58	19	]	]	PUNCT
ajst-21781	58	20	.	.	PUNCT
ajst-21781	59	1	topical	topical	ADJ
ajst-21781	59	2	corticosteroids	corticosteroid	NOUN
ajst-21781	59	3	and	and	CCONJ
ajst-21781	59	4	calcineurin	calcineurin	ADJ
ajst-21781	59	5	inhibitors	inhibitor	NOUN
ajst-21781	59	6	may	may	AUX
ajst-21781	59	7	be	be	AUX
ajst-21781	59	8	used	use	VERB
ajst-21781	59	9	as	as	ADP
ajst-21781	59	10	a	a	DET
ajst-21781	59	11	routine	routine	ADJ
ajst-21781	59	12	anti	anti	ADJ
ajst-21781	59	13	-	-	ADJ
ajst-21781	59	14	inflammatory	inflammatory	ADJ
ajst-21781	59	15	treatment	treatment	NOUN
ajst-21781	59	16	option[26	option[26	NOUN
ajst-21781	59	17	]	]	PUNCT
ajst-21781	59	18	.	.	PUNCT
ajst-21781	60	1	liu	liu	PROPN
ajst-21781	60	2	et	et	PROPN
ajst-21781	60	3	al	al	PROPN
ajst-21781	60	4	published	publish	VERB
ajst-21781	60	5	a	a	DET
ajst-21781	60	6	case	case	NOUN
ajst-21781	60	7	report	report	NOUN
ajst-21781	60	8	that	that	SCONJ
ajst-21781	60	9	crisaborole	crisaborole	NOUN
ajst-21781	60	10	2	2	NUM
ajst-21781	60	11	%	%	NOUN
ajst-21781	60	12	ointment	ointment	NOUN
ajst-21781	60	13	was	be	AUX
ajst-21781	60	14	effective	effective	ADJ
ajst-21781	60	15	in	in	ADP
ajst-21781	60	16	controlling	control	VERB
ajst-21781	60	17	seborrhoeic	seborrhoeic	PROPN
ajst-21781	60	18	dermatitis	dermatitis	NOUN
ajst-21781	60	19	at	at	ADP
ajst-21781	60	20	the	the	DET
ajst-21781	60	21	nasolabial	nasolabial	ADJ
ajst-21781	60	22	fold	fold	NOUN
ajst-21781	60	23	(	(	PUNCT
ajst-21781	60	24	50	50	NUM
ajst-21781	60	25	-	-	PUNCT
ajst-21781	60	26	year	year	NOUN
ajst-21781	60	27	-	-	PUNCT
ajst-21781	60	28	old	old	ADJ
ajst-21781	60	29	man)[9	man)[9	NOUN
ajst-21781	60	30	]	]	PUNCT
ajst-21781	60	31	.	.	PUNCT
ajst-21781	61	1	further	further	ADJ
ajst-21781	61	2	rcts	rct	NOUN
ajst-21781	61	3	are	be	AUX
ajst-21781	61	4	needed	need	VERB
ajst-21781	61	5	to	to	PART
ajst-21781	61	6	validate	validate	VERB
ajst-21781	61	7	the	the	DET
ajst-21781	61	8	clinical	clinical	ADJ
ajst-21781	61	9	efficacy	efficacy	NOUN
ajst-21781	61	10	of	of	ADP
ajst-21781	61	11	pde-4	pde-4	PUNCT
ajst-21781	61	12	in	in	ADP
ajst-21781	61	13	seborrhoeic	seborrhoeic	PROPN
ajst-21781	61	14	dermatitis	dermatitis	NOUN
ajst-21781	61	15	.	.	PUNCT
ajst-21781	62	1	8	8	NUM
ajst-21781	62	2	.	.	X
ajst-21781	63	1	conclusion	conclusion	NOUN
ajst-21781	63	2	inhibition	inhibition	NOUN
ajst-21781	63	3	of	of	ADP
ajst-21781	63	4	pde-4	pde-4	PRON
ajst-21781	63	5	effectively	effectively	ADV
ajst-21781	63	6	reduces	reduce	VERB
ajst-21781	63	7	intracellular	intracellular	ADJ
ajst-21781	63	8	camp	camp	NOUN
ajst-21781	63	9	levels	level	NOUN
ajst-21781	63	10	,	,	PUNCT
ajst-21781	63	11	resulting	result	VERB
ajst-21781	63	12	in	in	ADP
ajst-21781	63	13	a	a	DET
ajst-21781	63	14	variety	variety	NOUN
ajst-21781	63	15	of	of	ADP
ajst-21781	63	16	anti	anti	ADJ
ajst-21781	63	17	-	-	ADJ
ajst-21781	63	18	inflammatory	inflammatory	ADJ
ajst-21781	63	19	effects	effect	NOUN
ajst-21781	63	20	and	and	CCONJ
ajst-21781	63	21	promising	promise	VERB
ajst-21781	63	22	treatments	treatment	NOUN
ajst-21781	63	23	for	for	ADP
ajst-21781	63	24	chronic	chronic	ADJ
ajst-21781	63	25	inflammatory	inflammatory	ADJ
ajst-21781	63	26	skin	skin	NOUN
ajst-21781	63	27	diseases	disease	NOUN
ajst-21781	63	28	.	.	PUNCT
ajst-21781	64	1	currently	currently	ADV
ajst-21781	64	2	,	,	PUNCT
ajst-21781	64	3	apremilast	apremilast	PROPN
ajst-21781	64	4	has	have	AUX
ajst-21781	64	5	been	be	AUX
ajst-21781	64	6	approved	approve	VERB
ajst-21781	64	7	by	by	ADP
ajst-21781	64	8	the	the	DET
ajst-21781	64	9	fda	fda	PROPN
ajst-21781	64	10	for	for	ADP
ajst-21781	64	11	the	the	DET
ajst-21781	64	12	treatment	treatment	NOUN
ajst-21781	64	13	of	of	ADP
ajst-21781	64	14	psoriasis	psoriasis	NOUN
ajst-21781	64	15	and	and	CCONJ
ajst-21781	64	16	psoriatic	psoriatic	ADJ
ajst-21781	64	17	arthritis	arthritis	NOUN
ajst-21781	64	18	,	,	PUNCT
ajst-21781	64	19	and	and	CCONJ
ajst-21781	64	20	topical	topical	ADJ
ajst-21781	64	21	crisaborole	crisaborole	NOUN
ajst-21781	64	22	ointment	ointment	NOUN
ajst-21781	64	23	has	have	AUX
ajst-21781	64	24	been	be	AUX
ajst-21781	64	25	approved	approve	VERB
ajst-21781	64	26	for	for	ADP
ajst-21781	64	27	the	the	DET
ajst-21781	64	28	treatment	treatment	NOUN
ajst-21781	64	29	of	of	ADP
ajst-21781	64	30	ad	ad	NOUN
ajst-21781	64	31	.	.	PUNCT
ajst-21781	65	1	pde-4	pde-4	NOUN
ajst-21781	65	2	inhibitors	inhibitor	NOUN
ajst-21781	65	3	are	be	AUX
ajst-21781	65	4	not	not	PART
ajst-21781	65	5	only	only	ADV
ajst-21781	65	6	effective	effective	ADJ
ajst-21781	65	7	,	,	PUNCT
ajst-21781	65	8	but	but	CCONJ
ajst-21781	65	9	also	also	ADV
ajst-21781	65	10	relatively	relatively	ADV
ajst-21781	65	11	inexpensive	inexpensive	ADJ
ajst-21781	65	12	to	to	PART
ajst-21781	65	13	develop	develop	VERB
ajst-21781	65	14	,	,	PUNCT
ajst-21781	65	15	which	which	PRON
ajst-21781	65	16	is	be	AUX
ajst-21781	65	17	an	an	DET
ajst-21781	65	18	advantage	advantage	NOUN
ajst-21781	65	19	in	in	ADP
ajst-21781	65	20	the	the	DET
ajst-21781	65	21	choice	choice	NOUN
ajst-21781	65	22	of	of	ADP
ajst-21781	65	23	long	long	ADJ
ajst-21781	65	24	-	-	PUNCT
ajst-21781	65	25	term	term	NOUN
ajst-21781	65	26	maintenance	maintenance	NOUN
ajst-21781	65	27	therapy	therapy	NOUN
ajst-21781	65	28	.	.	PUNCT
ajst-21781	66	1	given	give	VERB
ajst-21781	66	2	that	that	SCONJ
ajst-21781	66	3	pde-4	pde-4	DET
ajst-21781	66	4	inhibitors	inhibitor	NOUN
ajst-21781	66	5	have	have	AUX
ajst-21781	66	6	only	only	ADV
ajst-21781	66	7	been	be	AUX
ajst-21781	66	8	in	in	ADP
ajst-21781	66	9	clinical	clinical	ADJ
ajst-21781	66	10	use	use	NOUN
ajst-21781	66	11	for	for	ADP
ajst-21781	66	12	a	a	DET
ajst-21781	66	13	relatively	relatively	ADV
ajst-21781	66	14	short	short	ADJ
ajst-21781	66	15	time	time	NOUN
ajst-21781	66	16	,	,	PUNCT
ajst-21781	66	17	large	large	ADJ
ajst-21781	66	18	,	,	PUNCT
ajst-21781	66	19	multi	multi	ADJ
ajst-21781	66	20	-	-	ADJ
ajst-21781	66	21	centre	centre	ADJ
ajst-21781	66	22	clinical	clinical	ADJ
ajst-21781	66	23	trials	trial	NOUN
ajst-21781	66	24	are	be	AUX
ajst-21781	66	25	still	still	ADV
ajst-21781	66	26	needed	need	VERB
ajst-21781	66	27	to	to	PART
ajst-21781	66	28	demonstrate	demonstrate	VERB
ajst-21781	66	29	and	and	CCONJ
ajst-21781	66	30	improve	improve	VERB
ajst-21781	66	31	their	their	PRON
ajst-21781	66	32	long	long	ADJ
ajst-21781	66	33	-	-	PUNCT
ajst-21781	66	34	term	term	NOUN
ajst-21781	66	35	efficacy	efficacy	NOUN
ajst-21781	66	36	and	and	CCONJ
ajst-21781	66	37	safety	safety	NOUN
ajst-21781	66	38	,	,	PUNCT
ajst-21781	66	39	and	and	CCONJ
ajst-21781	66	40	we	we	PRON
ajst-21781	66	41	look	look	VERB
ajst-21781	66	42	forward	forward	ADV
ajst-21781	66	43	to	to	ADP
ajst-21781	66	44	more	more	ADV
ajst-21781	66	45	effective	effective	ADJ
ajst-21781	66	46	pde-4	pde-4	ADJ
ajst-21781	66	47	inhibitortargeted	inhibitortargete	VERB
ajst-21781	66	48	drugs	drug	NOUN
ajst-21781	66	49	providing	provide	VERB
ajst-21781	66	50	viable	viable	ADJ
ajst-21781	66	51	options	option	NOUN
ajst-21781	66	52	for	for	ADP
ajst-21781	66	53	the	the	DET
ajst-21781	66	54	treatment	treatment	NOUN
ajst-21781	66	55	of	of	ADP
ajst-21781	66	56	chronic	chronic	ADJ
ajst-21781	66	57	inflammatory	inflammatory	ADJ
ajst-21781	66	58	dermatoses	dermatosis	NOUN
ajst-21781	66	59	in	in	ADP
ajst-21781	66	60	the	the	DET
ajst-21781	66	61	future	future	NOUN
ajst-21781	66	62	.	.	PUNCT
ajst-21781	67	1	168	168	NUM
ajst-21781	67	2	conflicts	conflict	NOUN
ajst-21781	67	3	of	of	ADP
ajst-21781	67	4	interest	interest	NOUN
ajst-21781	67	5	the	the	DET
ajst-21781	67	6	authors	author	NOUN
ajst-21781	67	7	declare	declare	VERB
ajst-21781	67	8	that	that	SCONJ
ajst-21781	67	9	they	they	PRON
ajst-21781	67	10	have	have	VERB
ajst-21781	67	11	no	no	DET
ajst-21781	67	12	conflict	conflict	NOUN
ajst-21781	67	13	of	of	ADP
ajst-21781	67	14	interest	interest	NOUN
ajst-21781	67	15	.	.	PUNCT
ajst-21781	68	1	acknowledgment	acknowledgment	NOUN
ajst-21781	68	2	none	none	NOUN
ajst-21781	68	3	.	.	PUNCT
ajst-21781	69	1	references	reference	NOUN
ajst-21781	69	2	[	[	X
ajst-21781	69	3	1	1	NUM
ajst-21781	69	4	]	]	SYM
ajst-21781	69	5	lugnier	lugni	ADJ
ajst-21781	69	6	c.	c.	PROPN
ajst-21781	69	7	cyclic	cyclic	PROPN
ajst-21781	69	8	nucleotide	nucleotide	NOUN
ajst-21781	69	9	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	69	10	(	(	PUNCT
ajst-21781	69	11	pde	pde	NOUN
ajst-21781	69	12	)	)	PUNCT
ajst-21781	69	13	superfamily	superfamily	NOUN
ajst-21781	69	14	:	:	PUNCT
ajst-21781	69	15	a	a	DET
ajst-21781	69	16	new	new	ADJ
ajst-21781	69	17	target	target	NOUN
ajst-21781	69	18	for	for	ADP
ajst-21781	69	19	the	the	DET
ajst-21781	69	20	development	development	NOUN
ajst-21781	69	21	of	of	ADP
ajst-21781	69	22	specific	specific	ADJ
ajst-21781	69	23	therapeutic	therapeutic	ADJ
ajst-21781	69	24	agents	agent	NOUN
ajst-21781	69	25	.	.	PUNCT
ajst-21781	70	1	pharmacol	pharmacol	VERB
ajst-21781	70	2	ther	ther	ADV
ajst-21781	70	3	.	.	PUNCT
ajst-21781	71	1	2006;109(3):366	2006;109(3):366	NUM
ajst-21781	71	2	-	-	SYM
ajst-21781	71	3	398	398	NUM
ajst-21781	71	4	.	.	PUNCT
ajst-21781	72	1	[	[	X
ajst-21781	72	2	2	2	NUM
ajst-21781	72	3	]	]	PUNCT
ajst-21781	72	4	de	de	X
ajst-21781	72	5	souza	souza	PROPN
ajst-21781	72	6	a	a	PROPN
ajst-21781	72	7	,	,	PUNCT
ajst-21781	72	8	strober	strober	ADV
ajst-21781	72	9	be	be	AUX
ajst-21781	72	10	,	,	PUNCT
ajst-21781	72	11	merola	merola	PROPN
ajst-21781	72	12	jf	jf	PROPN
ajst-21781	72	13	,	,	PUNCT
ajst-21781	72	14	oliver	oliver	PROPN
ajst-21781	72	15	s	s	PROPN
ajst-21781	72	16	,	,	PUNCT
ajst-21781	72	17	franks	franks	PROPN
ajst-21781	72	18	ag	ag	PROPN
ajst-21781	72	19	,	,	PUNCT
ajst-21781	72	20	jr	jr	PROPN
ajst-21781	72	21	.	.	PROPN
ajst-21781	72	22	apremilast	apremilast	VERB
ajst-21781	72	23	for	for	ADP
ajst-21781	72	24	discoid	discoid	PROPN
ajst-21781	72	25	lupus	lupus	PROPN
ajst-21781	72	26	erythematosus	erythematosus	NOUN
ajst-21781	72	27	:	:	PUNCT
ajst-21781	72	28	results	result	NOUN
ajst-21781	72	29	of	of	ADP
ajst-21781	72	30	a	a	DET
ajst-21781	72	31	phase	phase	NOUN
ajst-21781	72	32	2	2	NUM
ajst-21781	72	33	,	,	PUNCT
ajst-21781	72	34	open	open	ADJ
ajst-21781	72	35	-	-	PUNCT
ajst-21781	72	36	label	label	NOUN
ajst-21781	72	37	,	,	PUNCT
ajst-21781	72	38	single	single	ADJ
ajst-21781	72	39	-	-	PUNCT
ajst-21781	72	40	arm	arm	NOUN
ajst-21781	72	41	,	,	PUNCT
ajst-21781	72	42	pilot	pilot	NOUN
ajst-21781	72	43	study	study	NOUN
ajst-21781	72	44	.	.	PUNCT
ajst-21781	73	1	j	j	PROPN
ajst-21781	73	2	drugs	drug	NOUN
ajst-21781	73	3	dermatol	dermatol	NOUN
ajst-21781	73	4	.	.	PUNCT
ajst-21781	74	1	2012;11(10):1224	2012;11(10):1224	NUM
ajst-21781	74	2	-	-	SYM
ajst-21781	74	3	1226	1226	NUM
ajst-21781	74	4	.	.	PUNCT
ajst-21781	75	1	[	[	X
ajst-21781	75	2	3	3	X
ajst-21781	75	3	]	]	X
ajst-21781	75	4	eskandari	eskandari	ADJ
ajst-21781	75	5	n	n	CCONJ
ajst-21781	75	6	,	,	PUNCT
ajst-21781	75	7	mirmosayyeb	mirmosayyeb	PROPN
ajst-21781	75	8	o	o	NOUN
ajst-21781	75	9	,	,	PUNCT
ajst-21781	75	10	bordbari	bordbari	PROPN
ajst-21781	75	11	g	g	NOUN
ajst-21781	75	12	,	,	PUNCT
ajst-21781	75	13	bastan	bastan	ADJ
ajst-21781	75	14	r	r	NOUN
ajst-21781	75	15	,	,	PUNCT
ajst-21781	75	16	yousefi	yousefi	PROPN
ajst-21781	75	17	z	z	PROPN
ajst-21781	75	18	,	,	PUNCT
ajst-21781	75	19	andalib	andalib	PROPN
ajst-21781	75	20	a.	a.	NOUN
ajst-21781	75	21	a	a	DET
ajst-21781	75	22	short	short	ADJ
ajst-21781	75	23	review	review	NOUN
ajst-21781	75	24	on	on	ADP
ajst-21781	75	25	structure	structure	NOUN
ajst-21781	75	26	and	and	CCONJ
ajst-21781	75	27	role	role	NOUN
ajst-21781	75	28	of	of	ADP
ajst-21781	75	29	cyclic3',5'-adenosine	cyclic3',5'-adenosine	PROPN
ajst-21781	75	30	monophosphate	monophosphate	ADJ
ajst-21781	75	31	-	-	PUNCT
ajst-21781	75	32	specific	specific	ADJ
ajst-21781	75	33	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	75	34	4	4	NUM
ajst-21781	75	35	as	as	ADP
ajst-21781	75	36	a	a	DET
ajst-21781	75	37	treatment	treatment	NOUN
ajst-21781	75	38	tool	tool	NOUN
ajst-21781	75	39	.	.	PUNCT
ajst-21781	76	1	j	j	PROPN
ajst-21781	76	2	res	res	PROPN
ajst-21781	76	3	pharm	pharm	PROPN
ajst-21781	76	4	pract	pract	PROPN
ajst-21781	76	5	.	.	PUNCT
ajst-21781	77	1	2015;4(4):175	2015;4(4):175	NUM
ajst-21781	77	2	-	-	SYM
ajst-21781	77	3	181	181	NUM
ajst-21781	77	4	.	.	PUNCT
ajst-21781	78	1	[	[	X
ajst-21781	78	2	4	4	NUM
ajst-21781	78	3	]	]	X
ajst-21781	78	4	sakkas	sakkas	PROPN
ajst-21781	78	5	li	li	PROPN
ajst-21781	78	6	,	,	PUNCT
ajst-21781	78	7	mavropoulos	mavropoulo	NOUN
ajst-21781	78	8	a	a	X
ajst-21781	78	9	,	,	PUNCT
ajst-21781	78	10	bogdanos	bogdanos	PROPN
ajst-21781	78	11	dp	dp	PROPN
ajst-21781	78	12	.	.	PROPN
ajst-21781	78	13	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	78	14	4	4	NUM
ajst-21781	78	15	inhibitors	inhibitor	NOUN
ajst-21781	78	16	in	in	ADP
ajst-21781	78	17	immune	immune	NOUN
ajst-21781	78	18	-	-	PUNCT
ajst-21781	78	19	mediated	mediate	VERB
ajst-21781	78	20	diseases	disease	NOUN
ajst-21781	78	21	:	:	PUNCT
ajst-21781	78	22	mode	mode	NOUN
ajst-21781	78	23	of	of	ADP
ajst-21781	78	24	action	action	NOUN
ajst-21781	78	25	,	,	PUNCT
ajst-21781	78	26	clinical	clinical	ADJ
ajst-21781	78	27	applications	application	NOUN
ajst-21781	78	28	,	,	PUNCT
ajst-21781	78	29	current	current	ADJ
ajst-21781	78	30	and	and	CCONJ
ajst-21781	78	31	future	future	ADJ
ajst-21781	78	32	perspectives	perspective	NOUN
ajst-21781	78	33	.	.	PUNCT
ajst-21781	79	1	curr	curr	PROPN
ajst-21781	79	2	med	med	PROPN
ajst-21781	79	3	chem	chem	NOUN
ajst-21781	79	4	.	.	PUNCT
ajst-21781	80	1	2017;24(28):3054	2017;24(28):3054	X
ajst-21781	80	2	-	-	SYM
ajst-21781	80	3	3067	3067	NUM
ajst-21781	80	4	.	.	PUNCT
ajst-21781	81	1	[	[	X
ajst-21781	81	2	5	5	NUM
ajst-21781	81	3	]	]	X
ajst-21781	81	4	sbidian	sbidian	PROPN
ajst-21781	81	5	e	e	PROPN
ajst-21781	81	6	,	,	PUNCT
ajst-21781	81	7	chaimani	chaimani	X
ajst-21781	81	8	a	a	PRON
ajst-21781	81	9	,	,	PUNCT
ajst-21781	81	10	garcia	garcia	PROPN
ajst-21781	81	11	-	-	PUNCT
ajst-21781	81	12	doval	doval	PROPN
ajst-21781	82	1	i	i	PROPN
ajst-21781	82	2	,	,	PUNCT
ajst-21781	82	3	et	et	PROPN
ajst-21781	82	4	al	al	PROPN
ajst-21781	82	5	.	.	PUNCT
ajst-21781	83	1	systemic	systemic	ADJ
ajst-21781	83	2	pharmacological	pharmacological	ADJ
ajst-21781	83	3	treatments	treatment	NOUN
ajst-21781	83	4	for	for	ADP
ajst-21781	83	5	chronic	chronic	ADJ
ajst-21781	83	6	plaque	plaque	NOUN
ajst-21781	83	7	psoriasis	psoriasis	NOUN
ajst-21781	83	8	:	:	PUNCT
ajst-21781	83	9	a	a	DET
ajst-21781	83	10	network	network	NOUN
ajst-21781	83	11	meta	meta	NOUN
ajst-21781	83	12	-	-	PUNCT
ajst-21781	83	13	analysis	analysis	NOUN
ajst-21781	83	14	.	.	PUNCT
ajst-21781	84	1	cochrane	cochrane	NOUN
ajst-21781	84	2	database	database	PROPN
ajst-21781	84	3	syst	syst	PROPN
ajst-21781	84	4	rev	rev	PROPN
ajst-21781	84	5	.	.	PROPN
ajst-21781	85	1	2017;12(12):cd011535	2017;12(12):cd011535	NUM
ajst-21781	85	2	.	.	PUNCT
ajst-21781	86	1	[	[	X
ajst-21781	86	2	6	6	NUM
ajst-21781	86	3	]	]	SYM
ajst-21781	86	4	li	li	PROPN
ajst-21781	86	5	h	h	PROPN
ajst-21781	86	6	,	,	PUNCT
ajst-21781	86	7	zuo	zuo	PROPN
ajst-21781	86	8	j	j	PROPN
ajst-21781	86	9	,	,	PUNCT
ajst-21781	86	10	tang	tang	PROPN
ajst-21781	86	11	w.	w.	PROPN
ajst-21781	86	12	phosphodiesterase-4	phosphodiesterase-4	NOUN
ajst-21781	86	13	inhibitors	inhibitor	NOUN
ajst-21781	86	14	for	for	ADP
ajst-21781	86	15	the	the	DET
ajst-21781	86	16	treatment	treatment	NOUN
ajst-21781	86	17	of	of	ADP
ajst-21781	86	18	inflammatory	inflammatory	ADJ
ajst-21781	86	19	diseases	disease	NOUN
ajst-21781	86	20	.	.	PUNCT
ajst-21781	87	1	front	front	ADJ
ajst-21781	87	2	pharmacol	pharmacol	PROPN
ajst-21781	87	3	.	.	PUNCT
ajst-21781	87	4	2018;9:1048	2018;9:1048	NUM
ajst-21781	87	5	.	.	PUNCT
ajst-21781	88	1	[	[	X
ajst-21781	88	2	7	7	X
ajst-21781	88	3	]	]	X
ajst-21781	88	4	mehta	mehta	PROPN
ajst-21781	88	5	h	h	PROPN
ajst-21781	88	6	,	,	PUNCT
ajst-21781	88	7	sharma	sharma	PROPN
ajst-21781	88	8	a	a	PROPN
ajst-21781	88	9	,	,	PUNCT
ajst-21781	88	10	dogra	dogra	PROPN
ajst-21781	88	11	s.	s.	PROPN
ajst-21781	88	12	evolving	evolve	VERB
ajst-21781	88	13	utility	utility	NOUN
ajst-21781	88	14	of	of	ADP
ajst-21781	88	15	apremilast	apremilast	NOUN
ajst-21781	88	16	in	in	ADP
ajst-21781	88	17	dermatological	dermatological	ADJ
ajst-21781	88	18	disorders	disorder	NOUN
ajst-21781	88	19	for	for	ADP
ajst-21781	88	20	off	off	ADP
ajst-21781	88	21	-	-	PUNCT
ajst-21781	88	22	label	label	NOUN
ajst-21781	88	23	indications	indication	NOUN
ajst-21781	88	24	.	.	PUNCT
ajst-21781	89	1	clin	clin	PROPN
ajst-21781	89	2	exp	exp	NOUN
ajst-21781	89	3	dermatol	dermatol	NOUN
ajst-21781	89	4	.	.	PUNCT
ajst-21781	90	1	2022;47(12):2136	2022;47(12):2136	NUM
ajst-21781	90	2	-	-	SYM
ajst-21781	90	3	2149	2149	NUM
ajst-21781	90	4	.	.	PUNCT
ajst-21781	91	1	[	[	X
ajst-21781	91	2	8	8	NUM
ajst-21781	91	3	]	]	X
ajst-21781	91	4	crocetti	crocetti	PROPN
ajst-21781	91	5	l	l	PROPN
ajst-21781	91	6	,	,	PUNCT
ajst-21781	91	7	floresta	floresta	PROPN
ajst-21781	91	8	g	g	PROPN
ajst-21781	91	9	,	,	PUNCT
ajst-21781	91	10	cilibrizzi	cilibrizzi	NOUN
ajst-21781	91	11	a	a	NOUN
ajst-21781	91	12	,	,	PUNCT
ajst-21781	91	13	giovannoni	giovannoni	PROPN
ajst-21781	91	14	mp	mp	PROPN
ajst-21781	91	15	.	.	PUNCT
ajst-21781	92	1	an	an	DET
ajst-21781	92	2	overview	overview	NOUN
ajst-21781	92	3	of	of	ADP
ajst-21781	92	4	pde4	pde4	NOUN
ajst-21781	92	5	inhibitors	inhibitor	NOUN
ajst-21781	92	6	in	in	ADP
ajst-21781	92	7	clinical	clinical	ADJ
ajst-21781	92	8	trials	trial	NOUN
ajst-21781	92	9	:	:	PUNCT
ajst-21781	92	10	2010	2010	NUM
ajst-21781	92	11	to	to	ADP
ajst-21781	92	12	early	early	ADJ
ajst-21781	92	13	2022	2022	NUM
ajst-21781	92	14	.	.	PUNCT
ajst-21781	93	1	molecules	molecule	NOUN
ajst-21781	93	2	.	.	PUNCT
ajst-21781	94	1	2022;27(15	2022;27(15	NUM
ajst-21781	94	2	)	)	PUNCT
ajst-21781	94	3	.	.	PUNCT
ajst-21781	95	1	[	[	X
ajst-21781	95	2	9	9	NUM
ajst-21781	95	3	]	]	X
ajst-21781	95	4	nassim	nassim	PROPN
ajst-21781	95	5	d	d	PROPN
ajst-21781	95	6	,	,	PUNCT
ajst-21781	95	7	alajmi	alajmi	NOUN
ajst-21781	95	8	a	a	PRON
ajst-21781	95	9	,	,	PUNCT
ajst-21781	95	10	jfri	jfri	PROPN
ajst-21781	95	11	a	a	PRON
ajst-21781	95	12	,	,	PUNCT
ajst-21781	95	13	pehr	pehr	NOUN
ajst-21781	95	14	k.	k.	PROPN
ajst-21781	95	15	apremilast	apremilast	VERB
ajst-21781	95	16	in	in	ADP
ajst-21781	95	17	dermatology	dermatology	NOUN
ajst-21781	95	18	:	:	PUNCT
ajst-21781	95	19	a	a	DET
ajst-21781	95	20	review	review	NOUN
ajst-21781	95	21	of	of	ADP
ajst-21781	95	22	literature	literature	NOUN
ajst-21781	95	23	.	.	PUNCT
ajst-21781	96	1	dermatol	dermatol	NOUN
ajst-21781	96	2	ther	ther	ADV
ajst-21781	96	3	.	.	PUNCT
ajst-21781	97	1	2020;33(6):e14261	2020;33(6):e14261	X
ajst-21781	97	2	.	.	PUNCT
ajst-21781	98	1	[	[	X
ajst-21781	98	2	10	10	NUM
ajst-21781	98	3	]	]	X
ajst-21781	98	4	peng	peng	PROPN
ajst-21781	98	5	t	t	PROPN
ajst-21781	98	6	,	,	PUNCT
ajst-21781	98	7	gong	gong	PROPN
ajst-21781	98	8	j	j	PROPN
ajst-21781	98	9	,	,	PUNCT
ajst-21781	98	10	jin	jin	PROPN
ajst-21781	98	11	y	y	PROPN
ajst-21781	98	12	,	,	PUNCT
ajst-21781	98	13	et	et	PROPN
ajst-21781	98	14	al	al	PROPN
ajst-21781	98	15	.	.	PUNCT
ajst-21781	99	1	inhibitors	inhibitor	NOUN
ajst-21781	99	2	of	of	ADP
ajst-21781	99	3	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	99	4	as	as	ADP
ajst-21781	99	5	cancer	cancer	NOUN
ajst-21781	99	6	therapeutics	therapeutic	NOUN
ajst-21781	99	7	.	.	PUNCT
ajst-21781	100	1	eur	eur	PROPN
ajst-21781	100	2	j	j	PROPN
ajst-21781	100	3	med	med	PROPN
ajst-21781	100	4	chem	chem	NOUN
ajst-21781	100	5	.	.	PUNCT
ajst-21781	101	1	2018;150:742	2018;150:742	X
ajst-21781	101	2	-	-	SYM
ajst-21781	101	3	756	756	NUM
ajst-21781	101	4	.	.	PUNCT
ajst-21781	102	1	[	[	X
ajst-21781	102	2	11	11	NUM
ajst-21781	102	3	]	]	PUNCT
ajst-21781	102	4	cohen	cohen	PROPN
ajst-21781	102	5	sr	sr	PROPN
ajst-21781	102	6	,	,	PUNCT
ajst-21781	102	7	gordon	gordon	PROPN
ajst-21781	102	8	sc	sc	PROPN
ajst-21781	102	9	,	,	PUNCT
ajst-21781	102	10	lam	lam	PROPN
ajst-21781	102	11	ah	ah	INTJ
ajst-21781	102	12	,	,	PUNCT
ajst-21781	102	13	rosmarin	rosmarin	PROPN
ajst-21781	102	14	d.	d.	PROPN
ajst-21781	102	15	recalcitrant	recalcitrant	ADJ
ajst-21781	102	16	seborrheic	seborrheic	PROPN
ajst-21781	102	17	dermatitis	dermatitis	NOUN
ajst-21781	102	18	successfully	successfully	ADV
ajst-21781	102	19	treated	treat	VERB
ajst-21781	102	20	with	with	ADP
ajst-21781	102	21	apremilast	apremilast	NOUN
ajst-21781	102	22	.	.	PUNCT
ajst-21781	103	1	j	j	PROPN
ajst-21781	103	2	cutan	cutan	PROPN
ajst-21781	103	3	med	med	ADJ
ajst-21781	103	4	surg	surg	NOUN
ajst-21781	103	5	.	.	PUNCT
ajst-21781	104	1	2020;24(1):90	2020;24(1):90	NUM
ajst-21781	104	2	-	-	PUNCT
ajst-21781	104	3	91	91	NUM
ajst-21781	104	4	.	.	PUNCT
ajst-21781	105	1	[	[	X
ajst-21781	105	2	12	12	NUM
ajst-21781	105	3	]	]	PUNCT
ajst-21781	105	4	elhage	elhage	NOUN
ajst-21781	105	5	kg	kg	PROPN
ajst-21781	105	6	,	,	PUNCT
ajst-21781	105	7	zhao	zhao	PROPN
ajst-21781	105	8	r	r	PROPN
ajst-21781	105	9	,	,	PUNCT
ajst-21781	105	10	nakamura	nakamura	PROPN
ajst-21781	105	11	m.	m.	NOUN
ajst-21781	105	12	advancements	advancement	NOUN
ajst-21781	105	13	in	in	ADP
ajst-21781	105	14	the	the	DET
ajst-21781	105	15	treatment	treatment	NOUN
ajst-21781	105	16	of	of	ADP
ajst-21781	105	17	cutaneous	cutaneous	ADJ
ajst-21781	105	18	lupus	lupus	NOUN
ajst-21781	105	19	erythematosus	erythematosus	NOUN
ajst-21781	105	20	and	and	CCONJ
ajst-21781	105	21	dermatomyositis	dermatomyositis	PROPN
ajst-21781	105	22	:	:	PUNCT
ajst-21781	105	23	a	a	DET
ajst-21781	105	24	review	review	NOUN
ajst-21781	105	25	of	of	ADP
ajst-21781	105	26	the	the	DET
ajst-21781	105	27	literature	literature	NOUN
ajst-21781	105	28	.	.	PUNCT
ajst-21781	106	1	clin	clin	PROPN
ajst-21781	106	2	cosmet	cosmet	PROPN
ajst-21781	106	3	investig	investig	NOUN
ajst-21781	106	4	dermatol	dermatol	NOUN
ajst-21781	106	5	.	.	PUNCT
ajst-21781	107	1	2022;15:1815	2022;15:1815	NUM
ajst-21781	107	2	-	-	SYM
ajst-21781	107	3	1831	1831	NUM
ajst-21781	107	4	.	.	PUNCT
ajst-21781	108	1	[	[	X
ajst-21781	108	2	13	13	NUM
ajst-21781	108	3	]	]	PUNCT
ajst-21781	108	4	alharthy	alharthy	PROPN
ajst-21781	108	5	rf	rf	VERB
ajst-21781	108	6	,	,	PUNCT
ajst-21781	108	7	alharthy	alharthy	ADJ
ajst-21781	108	8	jm	jm	PROPN
ajst-21781	108	9	,	,	PUNCT
ajst-21781	108	10	bawazir	bawazir	PROPN
ajst-21781	108	11	ro	ro	PROPN
ajst-21781	108	12	,	,	PUNCT
ajst-21781	108	13	katib	katib	PROPN
ajst-21781	108	14	ri	ri	PROPN
ajst-21781	108	15	,	,	PUNCT
ajst-21781	108	16	alharthy	alharthy	PROPN
ajst-21781	108	17	fs	fs	PROPN
ajst-21781	108	18	.	.	PUNCT
ajst-21781	109	1	the	the	DET
ajst-21781	109	2	efficacy	efficacy	NOUN
ajst-21781	109	3	and	and	CCONJ
ajst-21781	109	4	safety	safety	NOUN
ajst-21781	109	5	of	of	ADP
ajst-21781	109	6	apremilast	apremilast	NOUN
ajst-21781	109	7	in	in	ADP
ajst-21781	109	8	the	the	DET
ajst-21781	109	9	management	management	NOUN
ajst-21781	109	10	of	of	ADP
ajst-21781	109	11	psoriatic	psoriatic	ADJ
ajst-21781	109	12	arthritis	arthritis	NOUN
ajst-21781	109	13	:	:	PUNCT
ajst-21781	109	14	a	a	DET
ajst-21781	109	15	systematic	systematic	ADJ
ajst-21781	109	16	review	review	NOUN
ajst-21781	109	17	and	and	CCONJ
ajst-21781	109	18	meta	meta	ADJ
ajst-21781	109	19	-	-	PUNCT
ajst-21781	109	20	analysis	analysis	NOUN
ajst-21781	109	21	.	.	PUNCT
ajst-21781	110	1	cureus	cureus	NOUN
ajst-21781	110	2	.	.	PUNCT
ajst-21781	111	1	2024;16(3):e55773	2024;16(3):e55773	NUM
ajst-21781	111	2	.	.	PUNCT
ajst-21781	112	1	[	[	X
ajst-21781	112	2	14	14	NUM
ajst-21781	112	3	]	]	X
ajst-21781	112	4	li	li	PROPN
ajst-21781	112	5	h	h	PROPN
ajst-21781	112	6	,	,	PUNCT
ajst-21781	112	7	zhang	zhang	PROPN
ajst-21781	112	8	z	z	PROPN
ajst-21781	112	9	,	,	PUNCT
ajst-21781	112	10	zhang	zhang	PROPN
ajst-21781	112	11	h	h	PROPN
ajst-21781	112	12	,	,	PUNCT
ajst-21781	112	13	guo	guo	PROPN
ajst-21781	112	14	y	y	PROPN
ajst-21781	112	15	,	,	PUNCT
ajst-21781	112	16	yao	yao	PROPN
ajst-21781	112	17	z.	z.	PROPN
ajst-21781	112	18	update	update	NOUN
ajst-21781	112	19	on	on	ADP
ajst-21781	112	20	the	the	DET
ajst-21781	112	21	pathogenesis	pathogenesis	NOUN
ajst-21781	112	22	and	and	CCONJ
ajst-21781	112	23	therapy	therapy	NOUN
ajst-21781	112	24	of	of	ADP
ajst-21781	112	25	atopic	atopic	NOUN
ajst-21781	112	26	dermatitis	dermatitis	NOUN
ajst-21781	112	27	.	.	PUNCT
ajst-21781	113	1	clin	clin	PROPN
ajst-21781	113	2	rev	rev	PROPN
ajst-21781	113	3	allergy	allergy	PROPN
ajst-21781	113	4	immunol	immunol	NOUN
ajst-21781	113	5	.	.	PUNCT
ajst-21781	114	1	2021;61(3):324	2021;61(3):324	NUM
ajst-21781	114	2	-	-	PUNCT
ajst-21781	114	3	338	338	NUM
ajst-21781	114	4	.	.	PUNCT
ajst-21781	115	1	[	[	X
ajst-21781	115	2	15	15	NUM
ajst-21781	115	3	]	]	X
ajst-21781	115	4	chu	chu	PROPN
ajst-21781	115	5	dk	dk	PROPN
ajst-21781	115	6	,	,	PUNCT
ajst-21781	115	7	chu	chu	PROPN
ajst-21781	115	8	awl	awl	PROPN
ajst-21781	115	9	,	,	PUNCT
ajst-21781	115	10	rayner	rayner	PROPN
ajst-21781	115	11	dg	dg	PROPN
ajst-21781	115	12	,	,	PUNCT
ajst-21781	115	13	et	et	PROPN
ajst-21781	115	14	al	al	PROPN
ajst-21781	115	15	.	.	PUNCT
ajst-21781	115	16	topical	topical	ADJ
ajst-21781	115	17	treatments	treatment	NOUN
ajst-21781	115	18	for	for	ADP
ajst-21781	115	19	atopic	atopic	NOUN
ajst-21781	115	20	dermatitis	dermatitis	NOUN
ajst-21781	115	21	(	(	PUNCT
ajst-21781	115	22	eczema	eczema	NOUN
ajst-21781	115	23	):	):	PUNCT
ajst-21781	115	24	systematic	systematic	ADJ
ajst-21781	115	25	review	review	NOUN
ajst-21781	115	26	and	and	CCONJ
ajst-21781	115	27	network	network	NOUN
ajst-21781	115	28	meta	meta	ADJ
ajst-21781	115	29	-	-	PUNCT
ajst-21781	115	30	analysis	analysis	NOUN
ajst-21781	115	31	of	of	ADP
ajst-21781	115	32	randomized	randomized	ADJ
ajst-21781	115	33	trials	trial	NOUN
ajst-21781	115	34	.	.	PUNCT
ajst-21781	116	1	j	j	PROPN
ajst-21781	116	2	allergy	allergy	PROPN
ajst-21781	116	3	clin	clin	PROPN
ajst-21781	116	4	immunol	immunol	PROPN
ajst-21781	116	5	.	.	PUNCT
ajst-21781	117	1	2023;152(6):1493	2023;152(6):1493	NUM
ajst-21781	117	2	-	-	SYM
ajst-21781	117	3	1519	1519	NUM
ajst-21781	117	4	.	.	PUNCT
ajst-21781	118	1	[	[	X
ajst-21781	118	2	16	16	NUM
ajst-21781	118	3	]	]	PUNCT
ajst-21781	118	4	sidbury	sidbury	PROPN
ajst-21781	118	5	r	r	NOUN
ajst-21781	118	6	,	,	PUNCT
ajst-21781	118	7	alikhan	alikhan	ADV
ajst-21781	118	8	a	a	PRON
ajst-21781	118	9	,	,	PUNCT
ajst-21781	118	10	bercovitch	bercovitch	NOUN
ajst-21781	118	11	l	l	NOUN
ajst-21781	118	12	,	,	PUNCT
ajst-21781	118	13	et	et	PROPN
ajst-21781	118	14	al	al	PROPN
ajst-21781	118	15	.	.	PUNCT
ajst-21781	118	16	guidelines	guideline	NOUN
ajst-21781	118	17	of	of	ADP
ajst-21781	118	18	care	care	NOUN
ajst-21781	118	19	for	for	ADP
ajst-21781	118	20	the	the	DET
ajst-21781	118	21	management	management	NOUN
ajst-21781	118	22	of	of	ADP
ajst-21781	118	23	atopic	atopic	NOUN
ajst-21781	118	24	dermatitis	dermatitis	NOUN
ajst-21781	118	25	in	in	ADP
ajst-21781	118	26	adults	adult	NOUN
ajst-21781	118	27	with	with	ADP
ajst-21781	118	28	topical	topical	ADJ
ajst-21781	118	29	therapies	therapy	NOUN
ajst-21781	118	30	.	.	PUNCT
ajst-21781	119	1	j	j	PROPN
ajst-21781	119	2	am	be	AUX
ajst-21781	119	3	acad	acad	ADJ
ajst-21781	119	4	dermatol	dermatol	NOUN
ajst-21781	119	5	.	.	PUNCT
ajst-21781	120	1	2023;89(1):e1	2023;89(1):e1	NUM
ajst-21781	120	2	-	-	PUNCT
ajst-21781	120	3	e20	e20	NOUN
ajst-21781	120	4	.	.	PUNCT
ajst-21781	121	1	[	[	X
ajst-21781	121	2	17	17	NUM
ajst-21781	121	3	]	]	X
ajst-21781	121	4	menter	menter	NOUN
ajst-21781	121	5	a	a	NOUN
ajst-21781	121	6	,	,	PUNCT
ajst-21781	121	7	gelfand	gelfand	PROPN
ajst-21781	121	8	jm	jm	PROPN
ajst-21781	121	9	,	,	PUNCT
ajst-21781	121	10	connor	connor	PROPN
ajst-21781	121	11	c	c	PROPN
ajst-21781	121	12	,	,	PUNCT
ajst-21781	121	13	et	et	PROPN
ajst-21781	121	14	al	al	PROPN
ajst-21781	121	15	.	.	PUNCT
ajst-21781	121	16	joint	joint	PROPN
ajst-21781	121	17	american	american	PROPN
ajst-21781	121	18	academy	academy	PROPN
ajst-21781	121	19	of	of	ADP
ajst-21781	121	20	dermatology	dermatology	NOUN
ajst-21781	121	21	-	-	PUNCT
ajst-21781	121	22	national	national	ADJ
ajst-21781	121	23	psoriasis	psoriasis	NOUN
ajst-21781	121	24	foundation	foundation	NOUN
ajst-21781	121	25	guidelines	guideline	NOUN
ajst-21781	121	26	of	of	ADP
ajst-21781	121	27	care	care	NOUN
ajst-21781	121	28	for	for	ADP
ajst-21781	121	29	the	the	DET
ajst-21781	121	30	management	management	NOUN
ajst-21781	121	31	of	of	ADP
ajst-21781	121	32	psoriasis	psoriasis	NOUN
ajst-21781	121	33	with	with	ADP
ajst-21781	121	34	systemic	systemic	ADJ
ajst-21781	121	35	nonbiologic	nonbiologic	ADJ
ajst-21781	121	36	therapies	therapy	NOUN
ajst-21781	121	37	.	.	PUNCT
ajst-21781	122	1	j	j	PROPN
ajst-21781	122	2	am	be	AUX
ajst-21781	122	3	acad	acad	ADJ
ajst-21781	122	4	dermatol	dermatol	NOUN
ajst-21781	122	5	.	.	PUNCT
ajst-21781	123	1	2020;82(6):1445	2020;82(6):1445	NOUN
ajst-21781	123	2	-	-	PUNCT
ajst-21781	123	3	1486	1486	NUM
ajst-21781	123	4	.	.	PUNCT
ajst-21781	124	1	[	[	X
ajst-21781	124	2	18	18	NUM
ajst-21781	124	3	]	]	X
ajst-21781	124	4	hong	hong	PROPN
ajst-21781	124	5	jj	jj	PROPN
ajst-21781	124	6	,	,	PUNCT
ajst-21781	124	7	mosca	mosca	PROPN
ajst-21781	124	8	ml	ml	PROPN
ajst-21781	124	9	,	,	PUNCT
ajst-21781	124	10	hadeler	hadeler	PROPN
ajst-21781	124	11	ek	ek	PROPN
ajst-21781	124	12	,	,	PUNCT
ajst-21781	124	13	brownstone	brownstone	NOUN
ajst-21781	124	14	nd	nd	PRON
ajst-21781	124	15	,	,	PUNCT
ajst-21781	124	16	bhutani	bhutani	PROPN
ajst-21781	124	17	t	t	PROPN
ajst-21781	124	18	,	,	PUNCT
ajst-21781	124	19	liao	liao	PROPN
ajst-21781	124	20	wj	wj	PROPN
ajst-21781	124	21	.	.	PUNCT
ajst-21781	125	1	genital	genital	ADJ
ajst-21781	125	2	and	and	CCONJ
ajst-21781	125	3	inverse	inverse	ADJ
ajst-21781	125	4	/	/	SYM
ajst-21781	125	5	intertriginous	intertriginous	ADJ
ajst-21781	125	6	psoriasis	psoriasis	NOUN
ajst-21781	125	7	:	:	PUNCT
ajst-21781	125	8	an	an	DET
ajst-21781	125	9	updated	update	VERB
ajst-21781	125	10	review	review	NOUN
ajst-21781	125	11	of	of	ADP
ajst-21781	125	12	therapies	therapy	NOUN
ajst-21781	125	13	and	and	CCONJ
ajst-21781	125	14	recommendations	recommendation	NOUN
ajst-21781	125	15	for	for	ADP
ajst-21781	125	16	practical	practical	ADJ
ajst-21781	125	17	management	management	NOUN
ajst-21781	125	18	.	.	PUNCT
ajst-21781	126	1	dermatol	dermatol	NOUN
ajst-21781	126	2	ther	ther	ADV
ajst-21781	126	3	(	(	PUNCT
ajst-21781	126	4	heidelb	heidelb	NOUN
ajst-21781	126	5	)	)	PUNCT
ajst-21781	126	6	.	.	PUNCT
ajst-21781	127	1	2021;11(3):833	2021;11(3):833	NUM
ajst-21781	127	2	-	-	PUNCT
ajst-21781	127	3	844	844	NUM
ajst-21781	127	4	.	.	PUNCT
ajst-21781	128	1	[	[	X
ajst-21781	128	2	19	19	NUM
ajst-21781	128	3	]	]	X
ajst-21781	128	4	leung	leung	PROPN
ajst-21781	128	5	yy	yy	PROPN
ajst-21781	128	6	,	,	PUNCT
ajst-21781	128	7	korotaeva	korotaeva	NOUN
ajst-21781	128	8	tv	tv	PROPN
ajst-21781	128	9	,	,	PUNCT
ajst-21781	128	10	candia	candia	PROPN
ajst-21781	128	11	l	l	PROPN
ajst-21781	128	12	,	,	PUNCT
ajst-21781	128	13	et	et	PROPN
ajst-21781	128	14	al	al	PROPN
ajst-21781	128	15	.	.	PUNCT
ajst-21781	128	16	management	management	NOUN
ajst-21781	128	17	of	of	ADP
ajst-21781	128	18	peripheral	peripheral	ADJ
ajst-21781	128	19	arthritis	arthritis	NOUN
ajst-21781	128	20	in	in	ADP
ajst-21781	128	21	patients	patient	NOUN
ajst-21781	128	22	with	with	ADP
ajst-21781	128	23	psoriatic	psoriatic	ADJ
ajst-21781	128	24	arthritis	arthritis	NOUN
ajst-21781	128	25	:	:	PUNCT
ajst-21781	128	26	an	an	DET
ajst-21781	128	27	updated	update	VERB
ajst-21781	128	28	literature	literature	NOUN
ajst-21781	128	29	review	review	NOUN
ajst-21781	128	30	informing	inform	VERB
ajst-21781	128	31	the	the	DET
ajst-21781	128	32	2021	2021	NUM
ajst-21781	128	33	grappa	grappa	NOUN
ajst-21781	128	34	treatment	treatment	NOUN
ajst-21781	128	35	recommendations	recommendation	NOUN
ajst-21781	128	36	.	.	PUNCT
ajst-21781	129	1	j	j	PROPN
ajst-21781	129	2	rheumatol	rheumatol	NOUN
ajst-21781	129	3	.	.	PUNCT
ajst-21781	130	1	2023;50(1):119130	2023;50(1):119130	NUM
ajst-21781	130	2	.	.	PUNCT
ajst-21781	131	1	[	[	X
ajst-21781	131	2	20	20	NUM
ajst-21781	131	3	]	]	PUNCT
ajst-21781	131	4	xu	xu	PROPN
ajst-21781	131	5	y	y	PROPN
ajst-21781	131	6	,	,	PUNCT
ajst-21781	131	7	li	li	PROPN
ajst-21781	131	8	z	z	PROPN
ajst-21781	131	9	,	,	PUNCT
ajst-21781	131	10	wu	wu	PROPN
ajst-21781	131	11	s	s	PROPN
ajst-21781	131	12	,	,	PUNCT
ajst-21781	131	13	guo	guo	PROPN
ajst-21781	131	14	l	l	PROPN
ajst-21781	131	15	,	,	PUNCT
ajst-21781	131	16	jiang	jiang	PROPN
ajst-21781	131	17	x.	x.	PROPN
ajst-21781	131	18	oral	oral	ADJ
ajst-21781	131	19	small	small	ADJ
ajst-21781	131	20	-	-	PUNCT
ajst-21781	131	21	molecule	molecule	NOUN
ajst-21781	131	22	tyrosine	tyrosine	NOUN
ajst-21781	131	23	kinase	kinase	NOUN
ajst-21781	131	24	2	2	NUM
ajst-21781	131	25	and	and	CCONJ
ajst-21781	131	26	phosphodiesterase	phosphodiesterase	NOUN
ajst-21781	131	27	4	4	NUM
ajst-21781	131	28	inhibitors	inhibitor	NOUN
ajst-21781	131	29	in	in	ADP
ajst-21781	131	30	plaque	plaque	NOUN
ajst-21781	131	31	psoriasis	psoriasis	NOUN
ajst-21781	131	32	:	:	PUNCT
ajst-21781	131	33	a	a	DET
ajst-21781	131	34	network	network	NOUN
ajst-21781	131	35	meta	meta	NOUN
ajst-21781	131	36	-	-	PUNCT
ajst-21781	131	37	analysis	analysis	NOUN
ajst-21781	131	38	.	.	PUNCT
ajst-21781	132	1	front	front	ADJ
ajst-21781	132	2	immunol	immunol	NOUN
ajst-21781	132	3	.	.	PUNCT
ajst-21781	133	1	2023;14:1180170	2023;14:1180170	X
ajst-21781	133	2	.	.	PUNCT
ajst-21781	134	1	[	[	X
ajst-21781	134	2	21	21	NUM
ajst-21781	134	3	]	]	X
ajst-21781	134	4	ezzedine	ezzedine	PROPN
ajst-21781	134	5	k	k	PROPN
ajst-21781	134	6	,	,	PUNCT
ajst-21781	134	7	vance	vance	PROPN
ajst-21781	134	8	tm	tm	PROPN
ajst-21781	134	9	,	,	PUNCT
ajst-21781	134	10	hamzavi	hamzavi	PROPN
ajst-21781	134	11	ih	ih	PRON
ajst-21781	134	12	,	,	PUNCT
ajst-21781	134	13	qureshi	qureshi	PROPN
ajst-21781	134	14	aa	aa	PROPN
ajst-21781	134	15	.	.	PUNCT
ajst-21781	135	1	vitiligo	vitiligo	PROPN
ajst-21781	135	2	:	:	PUNCT
ajst-21781	136	1	targeted	target	VERB
ajst-21781	136	2	therapies	therapy	NOUN
ajst-21781	136	3	add	add	VERB
ajst-21781	136	4	color	color	NOUN
ajst-21781	136	5	to	to	ADP
ajst-21781	136	6	disease	disease	NOUN
ajst-21781	136	7	pathophysiology	pathophysiology	NOUN
ajst-21781	136	8	.	.	PUNCT
ajst-21781	137	1	j	j	PROPN
ajst-21781	137	2	invest	invest	VERB
ajst-21781	137	3	dermatol	dermatol	NOUN
ajst-21781	137	4	.	.	PUNCT
ajst-21781	138	1	2020;140(8):1498	2020;140(8):1498	NUM
ajst-21781	138	2	-	-	SYM
ajst-21781	138	3	1500	1500	NUM
ajst-21781	138	4	.	.	PUNCT
ajst-21781	139	1	[	[	X
ajst-21781	139	2	22	22	NUM
ajst-21781	139	3	]	]	X
ajst-21781	139	4	perez	perez	PROPN
ajst-21781	139	5	-	-	PUNCT
ajst-21781	139	6	bootello	bootello	PROPN
ajst-21781	139	7	j	j	PROPN
ajst-21781	139	8	,	,	PUNCT
ajst-21781	139	9	cova	cova	PROPN
ajst-21781	139	10	-	-	PROPN
ajst-21781	139	11	martin	martin	PROPN
ajst-21781	139	12	r	r	PROPN
ajst-21781	139	13	,	,	PUNCT
ajst-21781	139	14	naharro	naharro	ADJ
ajst-21781	139	15	-	-	PUNCT
ajst-21781	139	16	rodriguez	rodriguez	PROPN
ajst-21781	139	17	j	j	PROPN
ajst-21781	139	18	,	,	PUNCT
ajst-21781	139	19	segurado	segurado	NOUN
ajst-21781	139	20	-	-	PUNCT
ajst-21781	139	21	miravalles	miravalle	NOUN
ajst-21781	139	22	g.	g.	NOUN
ajst-21781	139	23	vitiligo	vitiligo	VERB
ajst-21781	139	24	:	:	PUNCT
ajst-21781	139	25	pathogenesis	pathogenesis	NOUN
ajst-21781	139	26	and	and	CCONJ
ajst-21781	139	27	new	new	ADJ
ajst-21781	139	28	and	and	CCONJ
ajst-21781	139	29	emerging	emerge	VERB
ajst-21781	139	30	treatments	treatment	NOUN
ajst-21781	139	31	.	.	PUNCT
ajst-21781	140	1	int	int	PROPN
ajst-21781	140	2	j	j	PROPN
ajst-21781	140	3	mol	mol	ADP
ajst-21781	140	4	sci	sci	PROPN
ajst-21781	140	5	.	.	PUNCT
ajst-21781	140	6	2023;24(24	2023;24(24	NUM
ajst-21781	140	7	)	)	PUNCT
ajst-21781	140	8	.	.	PUNCT
ajst-21781	141	1	[	[	X
ajst-21781	141	2	23	23	NUM
ajst-21781	141	3	]	]	X
ajst-21781	141	4	sharma	sharma	PROPN
ajst-21781	141	5	s	s	PROPN
ajst-21781	141	6	,	,	PUNCT
ajst-21781	141	7	bhardwaj	bhardwaj	PROPN
ajst-21781	141	8	a	a	PROPN
ajst-21781	141	9	,	,	PUNCT
ajst-21781	141	10	dwivedi	dwivedi	PROPN
ajst-21781	141	11	p	p	PROPN
ajst-21781	141	12	,	,	PUNCT
ajst-21781	141	13	et	et	PROPN
ajst-21781	141	14	al	al	PROPN
ajst-21781	141	15	.	.	PROPN
ajst-21781	142	1	apremilast	apremilast	PROPN
ajst-21781	142	2	add	add	VERB
ajst-21781	142	3	-	-	PUNCT
ajst-21781	142	4	on	on	ADP
ajst-21781	142	5	benefits	benefit	NOUN
ajst-21781	142	6	over	over	ADP
ajst-21781	142	7	conventional	conventional	ADJ
ajst-21781	142	8	drugs	drug	NOUN
ajst-21781	142	9	(	(	PUNCT
ajst-21781	142	10	abcd	abcd	PROPN
ajst-21781	142	11	)	)	PUNCT
ajst-21781	142	12	in	in	ADP
ajst-21781	142	13	unstable	unstable	ADJ
ajst-21781	142	14	nonsegmental	nonsegmental	NOUN
ajst-21781	142	15	vitiligo	vitiligo	VERB
ajst-21781	142	16	:	:	PUNCT
ajst-21781	142	17	a	a	DET
ajst-21781	142	18	12	12	NUM
ajst-21781	142	19	-	-	PUNCT
ajst-21781	142	20	week	week	NOUN
ajst-21781	142	21	single	single	ADJ
ajst-21781	142	22	-	-	PUNCT
ajst-21781	142	23	center	center	NOUN
ajst-21781	142	24	randomized	randomize	VERB
ajst-21781	142	25	controlled	control	VERB
ajst-21781	142	26	trial	trial	NOUN
ajst-21781	142	27	.	.	PUNCT
ajst-21781	143	1	cureus	cureus	NOUN
ajst-21781	143	2	.	.	PUNCT
ajst-21781	144	1	2023;15(4):e37180	2023;15(4):e37180	X
ajst-21781	144	2	.	.	PUNCT
ajst-21781	145	1	[	[	X
ajst-21781	145	2	24	24	NUM
ajst-21781	145	3	]	]	X
ajst-21781	145	4	jafarzadeh	jafarzadeh	NOUN
ajst-21781	145	5	a	a	PRON
ajst-21781	145	6	,	,	PUNCT
ajst-21781	145	7	pour	pour	VERB
ajst-21781	145	8	mohammad	mohammad	PROPN
ajst-21781	145	9	a	a	PRON
ajst-21781	145	10	,	,	PUNCT
ajst-21781	145	11	khosravi	khosravi	VERB
ajst-21781	145	12	m	m	PROPN
ajst-21781	145	13	,	,	PUNCT
ajst-21781	145	14	et	et	PROPN
ajst-21781	145	15	al	al	PROPN
ajst-21781	145	16	.	.	PUNCT
ajst-21781	146	1	a	a	DET
ajst-21781	146	2	systematic	systematic	ADJ
ajst-21781	146	3	review	review	NOUN
ajst-21781	146	4	of	of	ADP
ajst-21781	146	5	case	case	NOUN
ajst-21781	146	6	series	series	NOUN
ajst-21781	146	7	and	and	CCONJ
ajst-21781	146	8	clinical	clinical	ADJ
ajst-21781	146	9	trials	trial	NOUN
ajst-21781	146	10	investigating	investigate	VERB
ajst-21781	146	11	systemic	systemic	ADJ
ajst-21781	146	12	oral	oral	ADJ
ajst-21781	146	13	or	or	CCONJ
ajst-21781	146	14	injectable	injectable	ADJ
ajst-21781	146	15	therapies	therapy	NOUN
ajst-21781	146	16	for	for	ADP
ajst-21781	146	17	the	the	DET
ajst-21781	146	18	treatment	treatment	NOUN
ajst-21781	146	19	of	of	ADP
ajst-21781	146	20	vitiligo	vitiligo	NOUN
ajst-21781	146	21	.	.	PUNCT
ajst-21781	147	1	skin	skin	NOUN
ajst-21781	147	2	res	re	NOUN
ajst-21781	147	3	technol	technol	NOUN
ajst-21781	147	4	.	.	PUNCT
ajst-21781	148	1	2024;30(3):e13642	2024;30(3):e13642	NUM
ajst-21781	148	2	.	.	PUNCT
ajst-21781	149	1	[	[	X
ajst-21781	149	2	25	25	NUM
ajst-21781	149	3	]	]	X
ajst-21781	149	4	saisorn	saisorn	PROPN
ajst-21781	149	5	w	w	PROPN
ajst-21781	149	6	,	,	PUNCT
ajst-21781	149	7	saithong	saithong	PROPN
ajst-21781	149	8	s	s	PROPN
ajst-21781	149	9	,	,	PUNCT
ajst-21781	149	10	phuengmaung	phuengmaung	NOUN
ajst-21781	149	11	p	p	NOUN
ajst-21781	149	12	,	,	PUNCT
ajst-21781	149	13	et	et	PROPN
ajst-21781	149	14	al	al	PROPN
ajst-21781	149	15	.	.	PROPN
ajst-21781	149	16	acute	acute	PROPN
ajst-21781	149	17	kidney	kidney	PROPN
ajst-21781	149	18	injury	injury	NOUN
ajst-21781	149	19	induced	induce	VERB
ajst-21781	149	20	lupus	lupus	NOUN
ajst-21781	149	21	exacerbation	exacerbation	NOUN
ajst-21781	149	22	through	through	ADP
ajst-21781	149	23	the	the	DET
ajst-21781	149	24	enhanced	enhanced	ADJ
ajst-21781	149	25	neutrophil	neutrophil	ADJ
ajst-21781	149	26	extracellular	extracellular	ADJ
ajst-21781	149	27	traps	trap	NOUN
ajst-21781	149	28	(	(	PUNCT
ajst-21781	149	29	and	and	CCONJ
ajst-21781	149	30	apoptosis	apoptosis	NOUN
ajst-21781	149	31	)	)	PUNCT
ajst-21781	149	32	in	in	ADP
ajst-21781	149	33	fcgr2b	fcgr2b	NOUN
ajst-21781	149	34	deficient	deficient	ADJ
ajst-21781	149	35	lupus	lupus	ADJ
ajst-21781	149	36	mice	mouse	NOUN
ajst-21781	149	37	with	with	ADP
ajst-21781	149	38	renal	renal	ADJ
ajst-21781	149	39	ischemia	ischemia	NOUN
ajst-21781	149	40	reperfusion	reperfusion	NOUN
ajst-21781	149	41	injury	injury	NOUN
ajst-21781	149	42	.	.	PUNCT
ajst-21781	150	1	front	front	ADJ
ajst-21781	150	2	immunol	immunol	NOUN
ajst-21781	150	3	.	.	PUNCT
ajst-21781	151	1	2021;12:669162	2021;12:669162	X
ajst-21781	151	2	.	.	PUNCT
ajst-21781	152	1	[	[	X
ajst-21781	152	2	26	26	NUM
ajst-21781	152	3	]	]	X
ajst-21781	152	4	jackson	jackson	PROPN
ajst-21781	152	5	jm	jm	PROPN
ajst-21781	152	6	,	,	PUNCT
ajst-21781	152	7	alexis	alexis	PROPN
ajst-21781	152	8	a	a	PROPN
ajst-21781	152	9	,	,	PUNCT
ajst-21781	152	10	zirwas	zirwas	PROPN
ajst-21781	152	11	m	m	PROPN
ajst-21781	152	12	,	,	PUNCT
ajst-21781	152	13	taylor	taylor	PROPN
ajst-21781	152	14	s.	s.	PROPN
ajst-21781	152	15	unmet	unmet	PROPN
ajst-21781	152	16	needs	need	VERB
ajst-21781	152	17	for	for	ADP
ajst-21781	152	18	patients	patient	NOUN
ajst-21781	152	19	with	with	ADP
ajst-21781	152	20	seborrheic	seborrheic	PROPN
ajst-21781	152	21	dermatitis	dermatitis	NOUN
ajst-21781	152	22	.	.	PUNCT
ajst-21781	153	1	j	j	PROPN
ajst-21781	153	2	am	be	AUX
ajst-21781	153	3	acad	acad	ADJ
ajst-21781	153	4	dermatol	dermatol	NOUN
ajst-21781	153	5	.	.	PUNCT
ajst-21781	154	1	2024;90(3):597	2024;90(3):597	NUM
ajst-21781	154	2	-	-	SYM
ajst-21781	154	3	604	604	NUM
ajst-21781	154	4	.	.	PUNCT